This document provides a summary of selected new evidence relevant to the NICE clinical guideline on the management of chronic obstructive pulmonary disease (COPD) in adults. It discusses 27 pieces of new evidence identified since the literature search was last conducted for the guideline. The evidence is grouped into the following sections: managing stable COPD, management of exacerbations, and areas not currently covered by NICE guidance. For stable COPD, the evidence discusses topics like smoking cessation, inhaled therapy, pulmonary rehabilitation, and vaccination. It finds that smoking cessation benefits may extend to more severe COPD, and counseling plus nicotine replacement or antidepressants can help patients stop smoking. For inhaled therapy, combinations of long-acting beta-
MANAGEMENT GUIDELINES FOR CHRONIC OBTRUCTIVE PULMONARY DISEASESoM
This summary provides the key points from the document in 3 sentences:
The document discusses guidelines for diagnosing and clinically managing COPD. It outlines that COPD is a highly prevalent but under-diagnosed disease that is multidimensional in nature and treatable. The guidelines recommend evaluating patients using tools like the BODE index to assess disease severity and choose effective therapies that can improve outcomes by treating the respiratory manifestations and associated systemic effects of COPD.
The document discusses various methods for assessing chronic obstructive pulmonary disease (COPD) including pulmonary function tests. It notes that while forced expiratory volume in 1 second (FEV1) is commonly used to diagnose and stage COPD severity, it does not reflect all disease impacts like dyspnea and exercise intolerance. Alternative tests that evaluate expiratory flow limitation and dynamic lung hyperinflation provide additional clinically useful information. A combination of tests including FEV1, inspiratory capacity, exercise testing, and measurements of lung volumes can help characterize an individual's COPD pathophysiology and guide management decisions.
Post Covid-19 Pulmonary Rehabilitationzuberchauhan
This document provides a review of post-COVID pulmonary rehabilitation. It begins with an abstract that outlines the background and aims to bring a pulmonary rehabilitation perspective to multidisciplinary COVID-19 treatment. The review analyzes prior studies on pulmonary rehabilitation to understand its potential benefits for COVID-19 patients suffering from long-term effects. It provides definitions of pulmonary rehabilitation and discusses considerations for both inpatient and outpatient rehabilitation programs with a focus on exercise recommendations.
This slide set provides an overview of the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines for chronic obstructive pulmonary disease (COPD). It defines COPD as a common lung disease characterized by airflow limitation caused by exposure to noxious particles or gases. The slide set outlines the GOLD board of directors and science committee, lists national leaders, and describes the objectives, evidence levels, and chapters covered in the 2017 GOLD report on defining, diagnosing, preventing, and managing COPD.
This document provides an updated global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (COPD) from the Global Initiative for Chronic Obstructive Lung Disease (GOLD). It discusses definitions of COPD, the disease burden, pathogenesis and pathophysiology. Guidelines are provided on diagnosis, assessment of symptoms and risk, therapeutic options including pharmacologic and non-pharmacologic treatments, management of stable COPD and exacerbations, and management of COPD comorbidities. The document is intended as a tool for healthcare professionals to implement effective COPD management programs.
This document provides guidelines for the management of patients with lung cancer in the United Kingdom. It covers all aspects of care from early detection and diagnosis to treatment and follow up. The guideline was developed by a multidisciplinary group and is intended to help standardize the coordinated approach required to treat lung cancer patients. It addresses symptoms that should prompt referral for testing, diagnostic tests, staging of cancer, treatment options including surgery, radiotherapy, chemotherapy and palliative care, as well as smoking cessation and supporting patients.
Respirology - 2022 - Barnett - Thoracic Society of Australia and New Zealand ...AssessoriadaGernciaG
This position paper from the Thoracic Society of Australia and New Zealand provides recommendations for acute oxygen use in adults. Key recommendations include:
1) Pulse oximetry should be routinely recorded along with vital signs to assess oxygenation. Arterial blood gases are still the gold standard but have limitations.
2) Oxygen is a drug that requires prescription documenting flow rate, delivery device, oxygen saturation targets, and criteria for deterioration or improvement.
3) The recommended oxygen saturation target range is 88-92% for those with chronic respiratory disease to avoid hypercapnia, and 92-96% for other situations.
4) Nasal cannulae are the preferred delivery method. Humidified
Home care services can benefit COPD patients by reducing hospital readmissions and time spent in the hospital. It facilitates discharge for severe COPD patients on long-term oxygen or ventilatory support. Home care is necessary for patients on chronic ventilatory support and helps compliance with pulmonary rehabilitation, but it is also costly so should only be used when clearly justified.
MANAGEMENT GUIDELINES FOR CHRONIC OBTRUCTIVE PULMONARY DISEASESoM
This summary provides the key points from the document in 3 sentences:
The document discusses guidelines for diagnosing and clinically managing COPD. It outlines that COPD is a highly prevalent but under-diagnosed disease that is multidimensional in nature and treatable. The guidelines recommend evaluating patients using tools like the BODE index to assess disease severity and choose effective therapies that can improve outcomes by treating the respiratory manifestations and associated systemic effects of COPD.
The document discusses various methods for assessing chronic obstructive pulmonary disease (COPD) including pulmonary function tests. It notes that while forced expiratory volume in 1 second (FEV1) is commonly used to diagnose and stage COPD severity, it does not reflect all disease impacts like dyspnea and exercise intolerance. Alternative tests that evaluate expiratory flow limitation and dynamic lung hyperinflation provide additional clinically useful information. A combination of tests including FEV1, inspiratory capacity, exercise testing, and measurements of lung volumes can help characterize an individual's COPD pathophysiology and guide management decisions.
Post Covid-19 Pulmonary Rehabilitationzuberchauhan
This document provides a review of post-COVID pulmonary rehabilitation. It begins with an abstract that outlines the background and aims to bring a pulmonary rehabilitation perspective to multidisciplinary COVID-19 treatment. The review analyzes prior studies on pulmonary rehabilitation to understand its potential benefits for COVID-19 patients suffering from long-term effects. It provides definitions of pulmonary rehabilitation and discusses considerations for both inpatient and outpatient rehabilitation programs with a focus on exercise recommendations.
This slide set provides an overview of the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines for chronic obstructive pulmonary disease (COPD). It defines COPD as a common lung disease characterized by airflow limitation caused by exposure to noxious particles or gases. The slide set outlines the GOLD board of directors and science committee, lists national leaders, and describes the objectives, evidence levels, and chapters covered in the 2017 GOLD report on defining, diagnosing, preventing, and managing COPD.
This document provides an updated global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (COPD) from the Global Initiative for Chronic Obstructive Lung Disease (GOLD). It discusses definitions of COPD, the disease burden, pathogenesis and pathophysiology. Guidelines are provided on diagnosis, assessment of symptoms and risk, therapeutic options including pharmacologic and non-pharmacologic treatments, management of stable COPD and exacerbations, and management of COPD comorbidities. The document is intended as a tool for healthcare professionals to implement effective COPD management programs.
This document provides guidelines for the management of patients with lung cancer in the United Kingdom. It covers all aspects of care from early detection and diagnosis to treatment and follow up. The guideline was developed by a multidisciplinary group and is intended to help standardize the coordinated approach required to treat lung cancer patients. It addresses symptoms that should prompt referral for testing, diagnostic tests, staging of cancer, treatment options including surgery, radiotherapy, chemotherapy and palliative care, as well as smoking cessation and supporting patients.
Respirology - 2022 - Barnett - Thoracic Society of Australia and New Zealand ...AssessoriadaGernciaG
This position paper from the Thoracic Society of Australia and New Zealand provides recommendations for acute oxygen use in adults. Key recommendations include:
1) Pulse oximetry should be routinely recorded along with vital signs to assess oxygenation. Arterial blood gases are still the gold standard but have limitations.
2) Oxygen is a drug that requires prescription documenting flow rate, delivery device, oxygen saturation targets, and criteria for deterioration or improvement.
3) The recommended oxygen saturation target range is 88-92% for those with chronic respiratory disease to avoid hypercapnia, and 92-96% for other situations.
4) Nasal cannulae are the preferred delivery method. Humidified
Home care services can benefit COPD patients by reducing hospital readmissions and time spent in the hospital. It facilitates discharge for severe COPD patients on long-term oxygen or ventilatory support. Home care is necessary for patients on chronic ventilatory support and helps compliance with pulmonary rehabilitation, but it is also costly so should only be used when clearly justified.
BTS_ICS Guideline for the Ventilatory Management of Acute Hypercapnic Respira...AssessoriadaGernciaG
This document provides guidelines for the ventilatory management of acute hypercapnic respiratory failure in adults, as developed by the British Thoracic Society/Intensive Care Society Acute Hypercapnic Respiratory Failure Guideline Development Group. It includes recommendations on the use of non-invasive ventilation and invasive mechanical ventilation. The guidelines cover various disease states that can cause acute hypercapnic respiratory failure such as COPD, asthma, cystic fibrosis, restrictive lung diseases and obesity hypoventilation syndrome. It also addresses weaning from mechanical ventilation, appropriate care environments, and end-of-life care considerations.
Transforming acute care in chronic obstructive pulmonary disease (COPD): Test...NHS Improvement
The document discusses projects in the UK that aimed to improve care for patients experiencing acute exacerbation of chronic obstructive pulmonary disease (COPD). It provides an overview of the challenges currently faced in COPD care, the improvement approaches taken by various NHS sites, and the emerging principles of success identified. Some of the key findings include:
1) Defining the patient pathway and understanding current performance and variations is important for prioritizing changes.
2) Implementing coordinated case management and ensuring access to specialist respiratory care can reduce length of stay and admissions.
3) Developing integrated acute care pathways with clear referral mechanisms improves quality and transforms the patient experience.
This document discusses supporting smoking cessation in healthcare. It explores gaps in understanding tobacco addiction and challenges in managing smoking cessation. The authors conducted a literature review and expert assessment to formulate recommendations. They found that smoking is not widely viewed as an addiction and few smokers seek help quitting from healthcare professionals. While professionals recognize advising patients to quit, barriers exist to doing so. Overall, more must be done to convince professionals that smoking is an addiction requiring treatment like other addictions.
home based pulmonaRY REHABILITATION IN COPDSurendra Ojha
This randomized study evaluated the impact of a home-based pulmonary rehabilitation program for subjects with COPD compared to a control group. The home-based program consisted of walking, stair climbing, and arm exercises performed 3 times per week for 24 sessions. The home-based group showed significant improvements in the 6-minute walk test distance (65m increase) and treadmill endurance time (316m increase) compared to no significant changes in the control group. The home-based group also had improvements in all domains of a quality of life questionnaire, while the control group did not change. The study demonstrates that a simple, low-cost home-based pulmonary rehabilitation program can improve exercise capacity and quality of life for subjects with COPD
A Study to Assess the Effectiveness of Abdominal Breathing Exercise in Reduct...ijtsrd
Background Abdominal breathing exercise is one among these. It reduces blood pressure by increasing baroreflex sensitivity and reducing sympathetic activity and chemo reflex activation. In India, it is reported that there are around 42 people are with pre hypertension, 15 are newly diagnose to have Hypertension and 31 are with known case of hypertension, and it kills nearly 8 million people every year worldwide. The noncompliance with treatment, stress and life style are found to be major reason for this doubling of disease within a decade, there “arises need for new therapies ‘and’ remedies. Objectives The study aimed to assess the effectiveness of abdominal breathing exercise in reducing mean blood pressure among hypertensive patients. Methods Pre experimental one group pre test – post test design was adopted for the study. 60 hypertensive patients from male and female medical general ward had been selected by convenient sampling. Tool comprised of Demographic proforma contained 9 items and sphygmomanometer, stethoscope and blood pressure monitoring table contained 3 items to record the readings. The reliability of the tool was tested by inter rater method and it was found to be r = 0.99. Abdominal breathing exercise was administered to the samples after pre assessment of mean blood pressure for ten minutes and post assessment of mean blood pressure is done at the gap of 5 minutes which is repeated 3 times a day and monitored for minimum of 3 days. ‘t’ test was used for finding the effectiveness, and Chi square test was used for finding out the association between mean blood pressure and selected demographic variables. Results It revealed that the mean differences in pre and post assessment was5.61 and ‘t’ value was 19.39 which is more than the ‘t’ table value. The overall findings of the study revealed that the Conclusion the study concluded that abdominal breathing exercise is found to be very effective in reducing the mean blood pressure. Arvind Singh Baghel | Dr. Neha Dubey | Bhoori Singh | Sunita Singh "A Study to Assess the Effectiveness of Abdominal Breathing Exercise in Reduction of Blood Pressure Among Hypertensive Patients in Selected Hospitals at Bhopal" Published in International Journal of Trend in Scientific Research and Development (ijtsrd), ISSN: 2456-6470, Volume-5 | Issue-4 , June 2021, URL: https://www.ijtsrd.compapers/ijtsrd42598.pdf Paper URL: https://www.ijtsrd.commedicine/nursing/42598/a-study-to-assess-the-effectiveness-of-abdominal-breathing-exercise-in-reduction-of-blood-pressure-among-hypertensive-patients-in-selected-hospitals-at-bhopal/arvind-singh-baghel
Bundles to prevent ventilator associated pneumoniapravin2k2
This document discusses ventilator-associated pneumonia (VAP), which is a common nosocomial infection in critically ill patients that leads to poor outcomes. It reviews guidelines for preventing VAP, including using orotracheal intubation, limiting circuit changes, and closed suctioning systems. It also describes the Ventilator Bundle, a set of evidence-based practices including elevating the head of the bed, daily sedation vacations, and DVT and stress ulcer prophylaxis that have been shown to reduce VAP rates more than individual measures. While effective, the bundle may not include all strategies recommended in guidelines, so modifying it or creating a specific VAP bundle is suggested.
Improving adult asthma care: emerging learning from the national improvement ...NHS Improvement
This document discusses NHS improvement projects aimed at improving care for adult asthma patients. It describes emerging lessons learned from various sites that are testing interventions like supportive self-management plans, medicines use reviews by pharmacists, and integrated care approaches. The overall goals are to define the patient care pathway, reduce variations, challenge existing systems, and identify principles that could help other organizations optimize asthma management and reduce burden on emergency care. Case studies provide examples of projects reducing accident and emergency re-attenders, implementing asthma care bundles, and creating an integrated care pathway.
This document reviews treatment and management strategies for chronic obstructive pulmonary disease (COPD). It finds that inhaled bronchodilators are the primary treatment for COPD patients. Pulmonary rehabilitation, including exercise and education, and smoking cessation are also important non-pharmacological strategies. For more severe COPD, guidelines recommend combination drug therapies using long-acting bronchodilators and inhaled corticosteroids to improve lung function and reduce exacerbations. Proper treatment and management can slow disease progression and improve quality of life for COPD patients.
This document summarizes a literature review on the effects of physical training on asthma in adults. The review analyzed 6 studies that involved a physical training intervention for adults with asthma, measuring effects on physical fitness, pulmonary function, asthma control, and quality of life. The studies generally found that physical training significantly improved measures of physical fitness like VO2max, but results on lung function were inconclusive. Some individual studies reported improvements in asthma control, severity, and quality of life with training, but overall the evidence is insufficient to conclude on effects in those areas. No studies reported any negative effects of exercise on asthma.
The meeting provided updates on current adherence projects and discussed ideas for future projects. For the current project on the bidirectional relationship between asthma outcomes and adherence, preliminary conclusions from Phase 2 were presented showing weak associations between adherence and control. Limitations were noted and next steps discussed. Two existing ideas for future studies using pharmacy and technology-based approaches were assessed for ongoing relevance, feasibility, validity and priority. New projects presented included a device optimization study and a project on age-related changes in childhood adherence and outcomes. Prioritization of adherence research needs and ensuring pursued priorities closed the discussion.
This document discusses a proposed project to increase the utilization of prone positioning for ARDS patients at a hospital. It begins with reviewing evidence that prone positioning can reduce mortality and improve oxygenation for ARDS patients. It then outlines a plan to develop a prone positioning protocol, educate staff, and implement the protocol. Evaluation of outcomes will occur after 90 days to determine if the protocol was successful in reducing mortality and improving oxygenation for ARDS patients. The goal is to implement an evidence-based intervention that can improve patient outcomes.
1) Chronic Obstructive Pulmonary Disease (COPD) is a progressive lung disease that causes shortness of breath. It includes emphysema, chronic bronchitis, and chronic asthma. Cigarette smoking is the primary cause.
2) Exercise can help people with COPD by improving cardiovascular health, reducing symptoms like breathlessness, and enhancing quality of life. Aerobic exercise, strength training, flexibility, and neuromuscular exercises are all beneficial.
3) Pulmonary rehabilitation including ongoing exercise is effective for improving quality of life and managing COPD symptoms. An individualized exercise program tailored to a person's capabilities is important.
Improving the quality and safety of home oxygen services: The case for spread NHS Improvement
The document discusses improving the quality and safety of home oxygen services through structured assessment and ongoing clinical review. It provides case studies from five sites that implemented home oxygen service-assessment and review (HOS-AR) as part of a national project. The project found that HOS-AR not only improves safety and quality but also increases cost efficiency, with some sites saving up to £400,000 per year through rationalizing unnecessary oxygen therapy. The case studies highlight practical service models for implementing HOS-AR and establishing it across the country.
Macrolide effects on the prevention of copd exacerbguidep
This document reviews the effects of macrolide antibiotics on preventing exacerbations in patients with chronic obstructive pulmonary disease (COPD). It summarizes several studies that have examined the impact of macrolides like erythromycin and clarithromycin on the frequency and severity of COPD exacerbations. The studies found that macrolide treatment reduced the number and rate of exacerbations as well as hospitalizations related to exacerbations. The document also discusses potential anti-inflammatory and other physiological mechanisms by which macrolides may help prevent COPD exacerbations.
The ProCESS trial found no significant difference in mortality between patients receiving protocol-based early goal-directed therapy (EGDT), protocol-based standard therapy, or usual care for early septic shock. While the EGDT group received fluid resuscitation more consistently, there were no differences in outcomes like mortality, organ failure, or length of stay. This prompted review by the Surviving Sepsis Campaign. They concluded that early diagnosis and treatment remain important. ProCESS did not assess patients with severe sepsis without shock. It also showed improved usual care since 2001, with mortality dropping from 46.5% to 18%, so key bundles should still be followed.
Dr. Sujay Halkur Shankar presented on the topic of weaning patients from mechanical ventilation. The presentation covered assessing patient readiness, different weaning methods like spontaneous breathing trials, factors that can cause difficulty weaning like respiratory, cardiac and neuromuscular issues, and post-extubation care. Spontaneous breathing trials are the preferred method of weaning and have higher rates of success than pressure support or intermittent mandatory ventilation. Factors that can contribute to weaning failure include increased respiratory load or drive, decreased respiratory muscle strength, and cardiac dysfunction induced by weaning.
Ventilator hyperinflation (VHI) is a physiotherapy technique used to deliver larger tidal volumes than baseline settings to intubated and mechanically ventilated patients. It aims to improve respiratory function by mobilizing secretions and restoring lung volume. The document outlines the indications, contraindications, procedure and advantages of VHI compared to manual hyperinflation. It also reviews a study that found no significant differences in outcomes between VHI and manual hyperinflation for sputum production, static compliance, oxygenation or cardiovascular stability. In conclusion, VHI is as safe and effective as manual hyperinflation but has advantages of maintaining PEEP and allowing for more accurate control and reproducibility of ventilation parameters.
The document discusses the GOLD 2003 update on the diagnosis and management of chronic obstructive pulmonary disease (COPD). It defines COPD and outlines criteria for diagnosing and classifying severity. It describes the four components of COPD management: assessing and monitoring the disease; reducing risk factors; managing stable COPD; and managing exacerbations. Pharmacologic and non-pharmacologic treatments are discussed for each component.
Whats New in GOLD 2022 Guidelines copy.pptxVishal Raj
The document discusses updates made in the 2022 GOLD guidelines for COPD. Key updates include:
- Adding COVID-19 and pertussis vaccination recommendations to tables.
- Adding fatigue as a new COPD symptom and criteria for 1-4 week follow up.
- Providing new definitions for early COPD, mild COPD, COPD in young people, and pre-COPD.
- Noting additional data on prevalence, economic burden, sex differences, and occupational exposures.
- Highlighting diffusing capacity of the lungs for carbon monoxide (DLCO) testing.
- Detailing evidence for pharmacological therapy in reducing lung function decline.
BTS_ICS Guideline for the Ventilatory Management of Acute Hypercapnic Respira...AssessoriadaGernciaG
This document provides guidelines for the ventilatory management of acute hypercapnic respiratory failure in adults, as developed by the British Thoracic Society/Intensive Care Society Acute Hypercapnic Respiratory Failure Guideline Development Group. It includes recommendations on the use of non-invasive ventilation and invasive mechanical ventilation. The guidelines cover various disease states that can cause acute hypercapnic respiratory failure such as COPD, asthma, cystic fibrosis, restrictive lung diseases and obesity hypoventilation syndrome. It also addresses weaning from mechanical ventilation, appropriate care environments, and end-of-life care considerations.
Transforming acute care in chronic obstructive pulmonary disease (COPD): Test...NHS Improvement
The document discusses projects in the UK that aimed to improve care for patients experiencing acute exacerbation of chronic obstructive pulmonary disease (COPD). It provides an overview of the challenges currently faced in COPD care, the improvement approaches taken by various NHS sites, and the emerging principles of success identified. Some of the key findings include:
1) Defining the patient pathway and understanding current performance and variations is important for prioritizing changes.
2) Implementing coordinated case management and ensuring access to specialist respiratory care can reduce length of stay and admissions.
3) Developing integrated acute care pathways with clear referral mechanisms improves quality and transforms the patient experience.
This document discusses supporting smoking cessation in healthcare. It explores gaps in understanding tobacco addiction and challenges in managing smoking cessation. The authors conducted a literature review and expert assessment to formulate recommendations. They found that smoking is not widely viewed as an addiction and few smokers seek help quitting from healthcare professionals. While professionals recognize advising patients to quit, barriers exist to doing so. Overall, more must be done to convince professionals that smoking is an addiction requiring treatment like other addictions.
home based pulmonaRY REHABILITATION IN COPDSurendra Ojha
This randomized study evaluated the impact of a home-based pulmonary rehabilitation program for subjects with COPD compared to a control group. The home-based program consisted of walking, stair climbing, and arm exercises performed 3 times per week for 24 sessions. The home-based group showed significant improvements in the 6-minute walk test distance (65m increase) and treadmill endurance time (316m increase) compared to no significant changes in the control group. The home-based group also had improvements in all domains of a quality of life questionnaire, while the control group did not change. The study demonstrates that a simple, low-cost home-based pulmonary rehabilitation program can improve exercise capacity and quality of life for subjects with COPD
A Study to Assess the Effectiveness of Abdominal Breathing Exercise in Reduct...ijtsrd
Background Abdominal breathing exercise is one among these. It reduces blood pressure by increasing baroreflex sensitivity and reducing sympathetic activity and chemo reflex activation. In India, it is reported that there are around 42 people are with pre hypertension, 15 are newly diagnose to have Hypertension and 31 are with known case of hypertension, and it kills nearly 8 million people every year worldwide. The noncompliance with treatment, stress and life style are found to be major reason for this doubling of disease within a decade, there “arises need for new therapies ‘and’ remedies. Objectives The study aimed to assess the effectiveness of abdominal breathing exercise in reducing mean blood pressure among hypertensive patients. Methods Pre experimental one group pre test – post test design was adopted for the study. 60 hypertensive patients from male and female medical general ward had been selected by convenient sampling. Tool comprised of Demographic proforma contained 9 items and sphygmomanometer, stethoscope and blood pressure monitoring table contained 3 items to record the readings. The reliability of the tool was tested by inter rater method and it was found to be r = 0.99. Abdominal breathing exercise was administered to the samples after pre assessment of mean blood pressure for ten minutes and post assessment of mean blood pressure is done at the gap of 5 minutes which is repeated 3 times a day and monitored for minimum of 3 days. ‘t’ test was used for finding the effectiveness, and Chi square test was used for finding out the association between mean blood pressure and selected demographic variables. Results It revealed that the mean differences in pre and post assessment was5.61 and ‘t’ value was 19.39 which is more than the ‘t’ table value. The overall findings of the study revealed that the Conclusion the study concluded that abdominal breathing exercise is found to be very effective in reducing the mean blood pressure. Arvind Singh Baghel | Dr. Neha Dubey | Bhoori Singh | Sunita Singh "A Study to Assess the Effectiveness of Abdominal Breathing Exercise in Reduction of Blood Pressure Among Hypertensive Patients in Selected Hospitals at Bhopal" Published in International Journal of Trend in Scientific Research and Development (ijtsrd), ISSN: 2456-6470, Volume-5 | Issue-4 , June 2021, URL: https://www.ijtsrd.compapers/ijtsrd42598.pdf Paper URL: https://www.ijtsrd.commedicine/nursing/42598/a-study-to-assess-the-effectiveness-of-abdominal-breathing-exercise-in-reduction-of-blood-pressure-among-hypertensive-patients-in-selected-hospitals-at-bhopal/arvind-singh-baghel
Bundles to prevent ventilator associated pneumoniapravin2k2
This document discusses ventilator-associated pneumonia (VAP), which is a common nosocomial infection in critically ill patients that leads to poor outcomes. It reviews guidelines for preventing VAP, including using orotracheal intubation, limiting circuit changes, and closed suctioning systems. It also describes the Ventilator Bundle, a set of evidence-based practices including elevating the head of the bed, daily sedation vacations, and DVT and stress ulcer prophylaxis that have been shown to reduce VAP rates more than individual measures. While effective, the bundle may not include all strategies recommended in guidelines, so modifying it or creating a specific VAP bundle is suggested.
Improving adult asthma care: emerging learning from the national improvement ...NHS Improvement
This document discusses NHS improvement projects aimed at improving care for adult asthma patients. It describes emerging lessons learned from various sites that are testing interventions like supportive self-management plans, medicines use reviews by pharmacists, and integrated care approaches. The overall goals are to define the patient care pathway, reduce variations, challenge existing systems, and identify principles that could help other organizations optimize asthma management and reduce burden on emergency care. Case studies provide examples of projects reducing accident and emergency re-attenders, implementing asthma care bundles, and creating an integrated care pathway.
This document reviews treatment and management strategies for chronic obstructive pulmonary disease (COPD). It finds that inhaled bronchodilators are the primary treatment for COPD patients. Pulmonary rehabilitation, including exercise and education, and smoking cessation are also important non-pharmacological strategies. For more severe COPD, guidelines recommend combination drug therapies using long-acting bronchodilators and inhaled corticosteroids to improve lung function and reduce exacerbations. Proper treatment and management can slow disease progression and improve quality of life for COPD patients.
This document summarizes a literature review on the effects of physical training on asthma in adults. The review analyzed 6 studies that involved a physical training intervention for adults with asthma, measuring effects on physical fitness, pulmonary function, asthma control, and quality of life. The studies generally found that physical training significantly improved measures of physical fitness like VO2max, but results on lung function were inconclusive. Some individual studies reported improvements in asthma control, severity, and quality of life with training, but overall the evidence is insufficient to conclude on effects in those areas. No studies reported any negative effects of exercise on asthma.
The meeting provided updates on current adherence projects and discussed ideas for future projects. For the current project on the bidirectional relationship between asthma outcomes and adherence, preliminary conclusions from Phase 2 were presented showing weak associations between adherence and control. Limitations were noted and next steps discussed. Two existing ideas for future studies using pharmacy and technology-based approaches were assessed for ongoing relevance, feasibility, validity and priority. New projects presented included a device optimization study and a project on age-related changes in childhood adherence and outcomes. Prioritization of adherence research needs and ensuring pursued priorities closed the discussion.
This document discusses a proposed project to increase the utilization of prone positioning for ARDS patients at a hospital. It begins with reviewing evidence that prone positioning can reduce mortality and improve oxygenation for ARDS patients. It then outlines a plan to develop a prone positioning protocol, educate staff, and implement the protocol. Evaluation of outcomes will occur after 90 days to determine if the protocol was successful in reducing mortality and improving oxygenation for ARDS patients. The goal is to implement an evidence-based intervention that can improve patient outcomes.
1) Chronic Obstructive Pulmonary Disease (COPD) is a progressive lung disease that causes shortness of breath. It includes emphysema, chronic bronchitis, and chronic asthma. Cigarette smoking is the primary cause.
2) Exercise can help people with COPD by improving cardiovascular health, reducing symptoms like breathlessness, and enhancing quality of life. Aerobic exercise, strength training, flexibility, and neuromuscular exercises are all beneficial.
3) Pulmonary rehabilitation including ongoing exercise is effective for improving quality of life and managing COPD symptoms. An individualized exercise program tailored to a person's capabilities is important.
Improving the quality and safety of home oxygen services: The case for spread NHS Improvement
The document discusses improving the quality and safety of home oxygen services through structured assessment and ongoing clinical review. It provides case studies from five sites that implemented home oxygen service-assessment and review (HOS-AR) as part of a national project. The project found that HOS-AR not only improves safety and quality but also increases cost efficiency, with some sites saving up to £400,000 per year through rationalizing unnecessary oxygen therapy. The case studies highlight practical service models for implementing HOS-AR and establishing it across the country.
Macrolide effects on the prevention of copd exacerbguidep
This document reviews the effects of macrolide antibiotics on preventing exacerbations in patients with chronic obstructive pulmonary disease (COPD). It summarizes several studies that have examined the impact of macrolides like erythromycin and clarithromycin on the frequency and severity of COPD exacerbations. The studies found that macrolide treatment reduced the number and rate of exacerbations as well as hospitalizations related to exacerbations. The document also discusses potential anti-inflammatory and other physiological mechanisms by which macrolides may help prevent COPD exacerbations.
The ProCESS trial found no significant difference in mortality between patients receiving protocol-based early goal-directed therapy (EGDT), protocol-based standard therapy, or usual care for early septic shock. While the EGDT group received fluid resuscitation more consistently, there were no differences in outcomes like mortality, organ failure, or length of stay. This prompted review by the Surviving Sepsis Campaign. They concluded that early diagnosis and treatment remain important. ProCESS did not assess patients with severe sepsis without shock. It also showed improved usual care since 2001, with mortality dropping from 46.5% to 18%, so key bundles should still be followed.
Dr. Sujay Halkur Shankar presented on the topic of weaning patients from mechanical ventilation. The presentation covered assessing patient readiness, different weaning methods like spontaneous breathing trials, factors that can cause difficulty weaning like respiratory, cardiac and neuromuscular issues, and post-extubation care. Spontaneous breathing trials are the preferred method of weaning and have higher rates of success than pressure support or intermittent mandatory ventilation. Factors that can contribute to weaning failure include increased respiratory load or drive, decreased respiratory muscle strength, and cardiac dysfunction induced by weaning.
Ventilator hyperinflation (VHI) is a physiotherapy technique used to deliver larger tidal volumes than baseline settings to intubated and mechanically ventilated patients. It aims to improve respiratory function by mobilizing secretions and restoring lung volume. The document outlines the indications, contraindications, procedure and advantages of VHI compared to manual hyperinflation. It also reviews a study that found no significant differences in outcomes between VHI and manual hyperinflation for sputum production, static compliance, oxygenation or cardiovascular stability. In conclusion, VHI is as safe and effective as manual hyperinflation but has advantages of maintaining PEEP and allowing for more accurate control and reproducibility of ventilation parameters.
The document discusses the GOLD 2003 update on the diagnosis and management of chronic obstructive pulmonary disease (COPD). It defines COPD and outlines criteria for diagnosing and classifying severity. It describes the four components of COPD management: assessing and monitoring the disease; reducing risk factors; managing stable COPD; and managing exacerbations. Pharmacologic and non-pharmacologic treatments are discussed for each component.
Whats New in GOLD 2022 Guidelines copy.pptxVishal Raj
The document discusses updates made in the 2022 GOLD guidelines for COPD. Key updates include:
- Adding COVID-19 and pertussis vaccination recommendations to tables.
- Adding fatigue as a new COPD symptom and criteria for 1-4 week follow up.
- Providing new definitions for early COPD, mild COPD, COPD in young people, and pre-COPD.
- Noting additional data on prevalence, economic burden, sex differences, and occupational exposures.
- Highlighting diffusing capacity of the lungs for carbon monoxide (DLCO) testing.
- Detailing evidence for pharmacological therapy in reducing lung function decline.
The document provides guidelines for the diagnosis and treatment of chronic obstructive pulmonary disease (COPD) from the European Respiratory Society and American Thoracic Society. It aims to improve COPD patient care, promote a disease-oriented approach, and be updated based on new evidence. The guidelines cover defining COPD, epidemiology, pathogenesis, diagnosis, management of stable COPD including pharmacological therapies, pulmonary rehabilitation, and smoking cessation.
Pulmonary rehabilitation is a multidisciplinary treatment for chronic respiratory diseases like COPD. It addresses the respiratory limitations and systemic consequences of the disease through exercise training, education, psychosocial support, and nutrition intervention. Studies show pulmonary rehabilitation improves outcomes like dyspnea, exercise capacity, and quality of life. It is now a standard treatment for COPD alongside bronchodilator therapy.
COPD is a common preventable disease characterized by persistent airflow limitation that is usually progressive. It is caused by exposure to noxious particles or gases, most commonly from cigarette smoking. COPD places a significant disease burden and is projected to become the third leading cause of death worldwide by 2020. The diagnosis is established through spirometry showing airflow obstruction that is not fully reversible. Disease severity is assessed based on symptoms, degree of airflow limitation, exacerbation frequency, and comorbidities. Treatment involves smoking cessation, pulmonary rehabilitation, pharmacotherapy including bronchodilators and inhaled corticosteroids, and management of exacerbations and complications. Prognosis can be estimated using the BODE index.
The document provides guidelines for diagnosing and assessing chronic obstructive pulmonary disease (COPD). Key points include:
- COPD is characterized by persistent airflow limitation associated with inflammation. A clinical diagnosis requires symptoms and risk factors plus spirometry showing airflow limitation.
- Tobacco smoking is the most common risk factor worldwide. Other risks include indoor and outdoor air pollution.
- Assessment of COPD involves evaluating symptoms, degree of airflow limitation via spirometry, risk of exacerbations, and comorbidities.
- Treatment aims to reduce symptoms and exacerbations while improving health status. Non-pharmacological and pharmacological options are outlined.
The document provides guidelines for diagnosing and assessing chronic obstructive pulmonary disease (COPD). Key points include:
- COPD is characterized by persistent airflow limitation associated with respiratory symptoms and exposure to noxious particles.
- A clinical diagnosis requires spirometry showing post-bronchodilator FEV1/FVC < 0.70.
- Assessment of COPD involves evaluating symptoms, degree of airflow limitation via spirometry, risk of exacerbations, and comorbidities.
- Treatment aims to reduce symptoms and exacerbations and improve health status.
This document discusses ventilator-associated pneumonia (VAP), which is a common nosocomial infection in critically ill patients that leads to poor outcomes. It reviews guidelines for preventing VAP, including using orotracheal intubation, limiting circuit changes, and closed suctioning systems. It also describes the Ventilator Bundle, a set of evidence-based practices including elevating the head of the bed, daily sedation vacations, and DVT and stress ulcer prophylaxis that have been shown to reduce VAP rates more than individual measures. While effective, the bundle may not include all strategies recommended in guidelines, so modifying it or creating a specific VAP bundle is suggested.
This document discusses comorbidities and systemic effects of chronic obstructive pulmonary disease (COPD). It begins by defining COPD and comorbidity, noting that COPD is considered a multicomponent disease. Smoking is identified as the main risk factor for COPD and is linked to several other diseases. The document then reviews the prevalence of various comorbidities in COPD patients, including cardiovascular, bone, and smoking-related conditions. It also discusses muscle wasting specifically, including its prevalence in COPD patients and factors involved in its pathogenesis.
Quick Reference Guide - BTS Guidelines for the Management of Community Acquir...WidyaPrawiraniSiahaa
This document provides guidelines for the management of community acquired pneumonia (CAP) in adults. It covers definitions of CAP, investigations that should be performed, and severity assessments. The key investigations recommended include chest x-rays, blood tests, sputum cultures, Legionella and pneumococcal urine antigens. Severity is assessed using the CRB65 score for patients managed in the community and the CURB65 score for hospitalized patients. Based on the scores, treatment recommendations are provided for either hospital or home management.
The document discusses the Global Initiative for Chronic Obstructive Lung Disease (GOLD) which provides guidelines for the management and treatment of COPD. GOLD was launched in 1997 with the objectives of recommending effective COPD prevention and management strategies worldwide and increasing awareness of COPD as a public health issue. The document defines COPD as a chronic lung disease characterized by persistent airflow limitation that is usually progressive. It also discusses factors that influence COPD development and progression, pathophysiology, diagnosis and assessment, therapeutic options including pharmacologic therapies, and the roles of bronchodilators in symptom management.
This document summarizes research on the effects of inhaled corticosteroids for the treatment of COPD. Key points include:
1) Inhaled corticosteroids produce small improvements in lung function and significantly better health status and reduced exacerbation frequency compared to no treatment, though they do not consistently modify airway inflammation.
2) Inhaled corticosteroids alone do not reduce the risk of death from COPD, but in combination with long-acting bronchodilators they provide additional clinical benefits including reduced exacerbations and improved health status.
3) Side effects of inhaled corticosteroids include a small increased risk of pneumonia; bone, eye, and other side effects are
This document discusses bronchodilators and their role in treating chronic obstructive pulmonary disease (COPD). It notes that bronchodilators are the mainstay of pharmacological COPD therapy and can improve symptoms, exercise tolerance, and reduce exacerbations. Both short-acting and long-acting bronchodilators are used, with short-acting for rescue of symptoms and long-acting as maintenance therapy. Common classes of bronchodilators include beta-agonists, anticholinergics, and methylxanthines. Combining different classes of bronchodilators can provide better efficacy than increasing the dose of a single agent.
This service provides free independent abstracts of medical publications. The abstracts are reviewed by the IPCRG research team to ensure relevance and accuracy. The abstracts summarize the main ideas but do not constitute treatment recommendations. Feedback on the abstracts is welcome.
This document discusses chronic obstructive pulmonary disease (COPD). It notes that COPD is a leading cause of death worldwide, with mortality expected to increase over 30% in the next decade without interventions. COPD is characterized by airflow limitation that is usually progressive and not fully reversible. Smoking is the primary risk factor. While COPD affects the lungs, it is also a systemic inflammatory disease. Lung hyperinflation and expiratory flow limitation are key pathophysiological features. Bronchodilators are the cornerstone of pharmacological treatment to reduce symptoms and exacerbations.
This document provides an introduction to the dissertation which aims to develop and evaluate a tool called the Assessment of Burden of COPD (ABC) tool. It first defines key concepts related to chronic disease management including health, chronic obstructive pulmonary disease (COPD), and the chronic care model. It emphasizes the importance of a holistic, patient-centered approach for COPD that incorporates patient-reported outcomes and self-management support. The document then states the need for a tool that can measure integrated health status, provide insight into a patient's disease, and facilitate shared decision making. The aim of the research is to develop and evaluate the effectiveness of such a tool focused on measuring and treating the experienced burden of COPD.
This document provides information about an upcoming conference on COPD novel therapeutics and management strategies taking place on October 22-23, 2012 in London. It lists key speakers from pharmaceutical companies, medical research institutions, and the NHS who will discuss topics like exacerbation prevention and management, drug development and novel targets, clinical trial design, and inhalation devices. The document also provides an agenda for the two-day conference and information on half-day workshops on developing inhalation devices and biomarkers in respiratory diseases taking place after the conference. Sponsorship and exhibition opportunities are mentioned.
The benefits of generic breathlessness rehabilitation in the UK and Canada - Dr Rachael Evans, Consultant Respiratory Physician
Presentation from the Breathlessness Symposium held in London on 1 July 2014
The latest guidelines on the management of a COPD patient ( Stable COPD, patient with an exacerbation of COPD), latest modalities of treatment of a COPD patient
This document provides guidance on using spirometry to diagnose chronic obstructive pulmonary disease (COPD) in primary care. It defines COPD and outlines how spirometry can help detect the disease earlier through measurements like FEV1. The document recommends training to properly perform and interpret spirometry. It provides tips for identifying at-risk patients and differentiating COPD from asthma using clinical features and reversibility testing.
This document provides guidance on reviewing polypharmacy, which is the use of multiple medications. It is important to review polypharmacy because many elderly patients are on multiple drugs but around half may not be taken as prescribed and adverse drug reactions are common, especially with more comorbidities rather than age. The guidance aims to help practitioners review medications and potentially deprescribe those where risks outweigh benefits by providing tools and considerations. Key points are identifying high-risk patients for review, focusing on certain drug classes, and balancing multiple treatment guidelines for individual patient circumstances through comprehensive medication reviews.
Este documento describe varios tipos de errores diagnósticos que pueden ocurrir en radiología, incluyendo errores de percepción, razonamiento, repetición y falta de conocimiento. Se presenta el caso de una paciente inmigrante cuya masa mediastínica aparente en un TAC resultó ser un artefacto causado por su pelo recogido, lo que ilustra la importancia de preparar adecuadamente a los pacientes antes de exámenes radiológicos para evitar falsas imágenes. Se enfatiza la necesidad de una buena
Tratamiento de las úlceras por presión traducidomaykamen
Las úlceras por presión son lesiones dolorosas que requieren un enfoque integral para la evaluación, el tratamiento y la prevención. La evaluación incluye la clasificación de la etapa de la úlcera, la nutrición del paciente y el alivio de la presión. El tratamiento se centra en reducir la presión, mejorar la nutrición, tratar el dolor y promover la cicatrización a través de apósitos y superficies de soporte especializadas. La prevención es fundamental a través de la posición adecu
El documento describe los pasos para gestionar tratamientos en una pantalla de una aplicación, incluyendo seleccionar la pestaña "Otras características", buscar un fármaco por su código, marca o principio activo, introducir los códigos de dos fármacos específicos, y hacer clic en "Aplicar" para ver una lista de pacientes asignados a esos tratamientos.
Este documento presenta el caso de una paciente que acudió a urgencias con dolor en el hipocondrio derecho. Se solicitó una serie de pruebas que mostraron una leucocitosis elevada de 20,000 con desviación a la izquierda y una infección urinaria. El médico hizo un juicio erróneo diagnosticando una infección urinaria y prescribiendo antibióticos, cuando los síntomas y hallazgos sugerían una colecistitis aguda. La paciente requirió una cirugía posterior para extirpar una vesícula gangren
Este documento presenta el caso clínico de un hombre francés de 64 años que fue traído al servicio de urgencias por dolor torácico atípico. Tras realizar exploraciones físicas y pruebas complementarias como análisis de sangre y radiografía de tórax, se descartó un evento agudo de isquemia coronaria. La radiografía de tórax reveló un neumotórax espontáneo primario. Finalmente, el paciente recibió el alta una vez que se descartó cualquier patología aguda del cor
El paciente presentó hiperpotasemia e insuficiencia renal aguda pre-renal debido al uso de AINEs, ARAII y ahorradores de potasio. Requirió tratamiento con fluidoterapia e insulina durante el ingreso hospitalario, lo que condujo a la corrección gradual de los niveles de potasio, creatinina y urea. Fue dado de alta con cifras en vías de normalización.
Este documento describe el contenido recomendado para el maletín personal de un médico de cabecera, incluyendo material para diagnóstico, tratamiento y emergencias. Un maletín bien equipado permite al médico realizar varios procedimientos y resolver problemas de salud de manera oportuna. El contenido propuesto debe adaptarse a las necesidades locales y capacidades del médico. Un maletín equipado apoya la accesibilidad, polivalencia y capacidad de respuesta que caracterizan al médico de familia.
Este documento presenta los resultados de un estudio que comparó los eventos de accidente cerebrovascular o embolismo sistémico entre un grupo que recibió DAB 300 y un grupo que recibió WARF durante 1 y 2 años. Después de 1 año, el 1,11% del grupo DAB 300 experimentó dichos eventos en comparación con el 1,71% del grupo WARF. Después de 2 años, las tasas fueron del 2,21% para el grupo DAB 300 y del 3,35% para el grupo WARF. Ambos resultados mostraron una reducción de riesgo similar
Cómo ejercer una medicina armónica claves para una práctica clínica clemente...maykamen
Este documento presenta tres claves para ejercer una medicina armónica que equilibre los enfoques científico y humano. 1) El objetivo de los médicos es reducir la morbilidad y mortalidad innecesariamente prematura y evitable, no evitar la muerte o enfermedad en general. 2) Los médicos deben considerar las éticas de la ignorancia y la negativa. 3) Se requiere compasión, cortesía y ternura con los pacientes y sus familias.
Este documento resume las recomendaciones del uso de dabigatrán para la fibrilación auricular no valvular. 1) Con buen control del INR, se recomienda débilmente la warfarina en lugar de dabigatrán. 2) Con mal control del INR, se recomienda débilmente dabigatrán en lugar de warfarina. 3) En caso de elegir dabigatrán, se recomienda débilmente dabigatrán de 300mg en lugar de 220mg.
Este documento habla sobre la alimentación saludable y contiene 3 oraciones. Presenta imágenes históricas de personas haciendo cola para obtener alimentos después de la guerra y de niños refugiados recibiendo pan. También incluye gráficos como la pirámide de los alimentos, la rueda de los alimentos y su versión nueva, e imágenes sobre el efecto de la publicidad en los hábitos alimenticios. El documento concluye agradeciendo y dando la dirección de un blog sobre salud y alimentación
1) El documento analiza los resultados de dos estudios clínicos que miden la efectividad de dos fármacos, simvastatina y rosuvastatina.
2) Calcula el número de pacientes que se benefician con cada fármaco versus los que no se benefician. Con simvastatina, por cada 1 paciente beneficiado, hay 27 en los que no es efectivo. Con rosuvastatina, por cada 1 beneficiado, entre 59-126 no lo son.
3) Señala que atribuir el beneficio a todos los pacientes sanos es un
Este documento presenta una evaluación GRADE de dabigatrán para la fibrilación auricular no valvular. Resumiendo: Dabigatrán a dosis de 220 mg y 300 mg dos veces al día redujo el riesgo de accidente cerebrovascular e ictus en comparación con la warfarina, con un mayor riesgo de hemorragia gastrointestinal para la dosis más alta. La calidad del control de la INR afectó los resultados. Dabigatrán carece de antídoto para revertir hemorragias, lo que es un inconveniente frente a la warfar
Este documento presenta una evaluación GRADE del fármaco dabigatrán para la prevención de accidentes cerebrovasculares y embolismos sistémicos en pacientes con fibrilación auricular no valvular. Resume los estudios clínicos que comparan dabigatrán con warfarina, analizando variables de resultados como ACV, hemorragias y funciones hepáticas. También analiza subgrupos de pacientes y concluye que dabigatrán reduce el riesgo de ACV y hemorragias graves respecto a warfarina, a
Este documento resume las críticas de un comité de evaluación de medicamentos de Euskadi a la publicidad del medicamento Duodart. El comité critica que la publicidad enfatiza solo los beneficios del medicamento frente a tamsulosina pero no menciona que no hubo diferencias significativas frente a dutasterida, que también era un objetivo principal. El comité también proporciona la bibliografía original del folleto promocional criticado.
Histololgy of Female Reproductive System.pptxAyeshaZaid1
Dive into an in-depth exploration of the histological structure of female reproductive system with this comprehensive lecture. Presented by Dr. Ayesha Irfan, Assistant Professor of Anatomy, this presentation covers the Gross anatomy and functional histology of the female reproductive organs. Ideal for students, educators, and anyone interested in medical science, this lecture provides clear explanations, detailed diagrams, and valuable insights into female reproductive system. Enhance your knowledge and understanding of this essential aspect of human biology.
Lecture 6 -- Memory 2015.pptlearning occurs when a stimulus (unconditioned st...AyushGadhvi1
learning occurs when a stimulus (unconditioned stimulus) eliciting a response (unconditioned response) • is paired with another stimulus (conditioned stimulus)
5-hydroxytryptamine or 5-HT or Serotonin is a neurotransmitter that serves a range of roles in the human body. It is sometimes referred to as the happy chemical since it promotes overall well-being and happiness.
It is mostly found in the brain, intestines, and blood platelets.
5-HT is utilised to transport messages between nerve cells, is known to be involved in smooth muscle contraction, and adds to overall well-being and pleasure, among other benefits. 5-HT regulates the body's sleep-wake cycles and internal clock by acting as a precursor to melatonin.
It is hypothesised to regulate hunger, emotions, motor, cognitive, and autonomic processes.
low birth weight presentation. Low birth weight (LBW) infant is defined as the one whose birth weight is less than 2500g irrespective of their gestational age. Premature birth and low birth weight(LBW) is still a serious problem in newborn. Causing high morbidity and mortality rate worldwide. The nursing care provide to low birth weight babies is crucial in promoting their overall health and development. Through careful assessment, diagnosis,, planning, and evaluation plays a vital role in ensuring these vulnerable infants receive the specialize care they need. In India every third of the infant weight less than 2500g.
Birth period, socioeconomical status, nutritional and intrauterine environment are the factors influencing low birth weight
Cell Therapy Expansion and Challenges in Autoimmune DiseaseHealth Advances
There is increasing confidence that cell therapies will soon play a role in the treatment of autoimmune disorders, but the extent of this impact remains to be seen. Early readouts on autologous CAR-Ts in lupus are encouraging, but manufacturing and cost limitations are likely to restrict access to highly refractory patients. Allogeneic CAR-Ts have the potential to broaden access to earlier lines of treatment due to their inherent cost benefits, however they will need to demonstrate comparable or improved efficacy to established modalities.
In addition to infrastructure and capacity constraints, CAR-Ts face a very different risk-benefit dynamic in autoimmune compared to oncology, highlighting the need for tolerable therapies with low adverse event risk. CAR-NK and Treg-based therapies are also being developed in certain autoimmune disorders and may demonstrate favorable safety profiles. Several novel non-cell therapies such as bispecific antibodies, nanobodies, and RNAi drugs, may also offer future alternative competitive solutions with variable value propositions.
Widespread adoption of cell therapies will not only require strong efficacy and safety data, but also adapted pricing and access strategies. At oncology-based price points, CAR-Ts are unlikely to achieve broad market access in autoimmune disorders, with eligible patient populations that are potentially orders of magnitude greater than the number of currently addressable cancer patients. Developers have made strides towards reducing cell therapy COGS while improving manufacturing efficiency, but payors will inevitably restrict access until more sustainable pricing is achieved.
Despite these headwinds, industry leaders and investors remain confident that cell therapies are poised to address significant unmet need in patients suffering from autoimmune disorders. However, the extent of this impact on the treatment landscape remains to be seen, as the industry rapidly approaches an inflection point.
10 Benefits an EPCR Software should Bring to EMS Organizations Traumasoft LLC
The benefits of an ePCR solution should extend to the whole EMS organization, not just certain groups of people or certain departments. It should provide more than just a form for entering and a database for storing information. It should also include a workflow of how information is communicated, used and stored across the entire organization.
NAVIGATING THE HORIZONS OF TIME LAPSE EMBRYO MONITORING.pdfRahul Sen
Time-lapse embryo monitoring is an advanced imaging technique used in IVF to continuously observe embryo development. It captures high-resolution images at regular intervals, allowing embryologists to select the most viable embryos for transfer based on detailed growth patterns. This technology enhances embryo selection, potentially increasing pregnancy success rates.
Kosmoderma Academy, a leading institution in the field of dermatology and aesthetics, offers comprehensive courses in cosmetology and trichology. Our specialized courses on PRP (Hair), DR+Growth Factor, GFC, and Qr678 are designed to equip practitioners with advanced skills and knowledge to excel in hair restoration and growth treatments.
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotesPsychoTech Services
A proprietary approach developed by bringing together the best of learning theories from Psychology, design principles from the world of visualization, and pedagogical methods from over a decade of training experience, that enables you to: Learn better, faster!
Are you looking for a long-lasting solution to your missing tooth?
Dental implants are the most common type of method for replacing the missing tooth. Unlike dentures or bridges, implants are surgically placed in the jawbone. In layman’s terms, a dental implant is similar to the natural root of the tooth. It offers a stable foundation for the artificial tooth giving it the look, feel, and function similar to the natural tooth.
3. Contents
Introduction ...................................................................................................... 4
Key messages ................................................................................................. 5
1 Commentary on new evidence ................................................................. 7
1.1 Diagnosing COPD .............................................................................. 7
1.2 Managing stable COPD ...................................................................... 7
1.3 Management of exacerbations of COPD .......................................... 18
Areas not currently covered by NICE guidance .......................................... 20
2 New evidence uncertainties .................................................................... 21
Appendix A: Methodology .............................................................................. 22
Appendix B: The Evidence Update Advisory Group and NHS Evidence
project team ................................................................................................... 25
Evidence Update 5 – Chronic obstructive pulmonary disease (February 2012) 3
4. Introduction
This Evidence Update identifies new evidence that might reinforce or generate future change
to the practice laid out in the following reference guidance:
1
Chronic obstructive pulmonary disease. NICE clinical guideline 101 (2010).
Available from www.nice.org.uk/guidance/CG101
Over 4000 pieces of evidence were identified and assessed, of which 27 were selected for
the Evidence Update (see Appendix A for details of the evidence search and selection
process). An Evidence Update Advisory Group (EUAG), comprised of subject experts,
reviewed the prioritised evidence (with additional input from internal experts) and provided a
commentary.
Other relevant NICE guidance
The focus of the Evidence Update is on the guidance stated above. However, overlap with
other NICE guidance has been outlined as part of the Evidence Update process. Where
relevant, this Evidence Update also makes reference to the following guidance:
1
Roflumilast for the management of severe chronic obstructive pulmonary disease. NICE
technology appraisal 244 (2012). Available from www.nice.org.uk/guidance/TA244
2
Varenicline for smoking cessation. NICE technology appraisal 123 (2007). Available from
www.nice.org.uk/guidance/TA123
Other relevant guidance
The following guidance is also of relevance to UK chronic obstructive pulmonary disease
(COPD) practice, however the Evidence Update does not discuss any potential effect the new
evidence may have on their recommendations:
British Thoracic Society Standards of Care Subcommittee on Pulmonary Rehabilitation
(2001) Pulmonary rehabilitation guideline. Thorax 56: 827–34
Available from www.brit-thoracic.org.uk/guidelines/pulmonary-rehabilitation-
guidelines.aspx
O’Driscoll BR, Howard LS, Davison AG (2008) British Thoracic Society Guideline for
emergency oxygen use in adult patients. Thorax 63 (suppl 6): 1–68
Available from www.brit-thoracic.org.uk/guidelines/emergency-oxygen-use-in-adult-
patients.aspx
Feedback
If you have any comments you would like to make on this Evidence Update, please email
contactus@evidence.nhs.uk
1
NICE-accredited guidance is denoted by the accreditation symbol
2
Guidance published prior to NICE accreditation
Evidence Update 5 – Chronic obstructive pulmonary disease (February 2012) 4
5. Key messages
The following table summarises what the EUAG decided were the key messages from the
Evidence Update. It also indicates the EUAG’s opinion on whether new evidence identified by
the Evidence Update reinforces or has potential to generate future change to the current
guidance listed in the introduction.
The relevant NICE guidance development centres have been made aware of this evidence,
which will be considered when guidance is reviewed. For further details of the evidence
behind these key messages and the specific guidance that may be affected, please see the
full commentaries.
Effect on guidance
Potential No
Key message
change change
Managing stable COPD
Smoking cessation
The potential health benefits of smoking cessation in people
with chronic obstructive pulmonary disease (COPD) appear to
be confirmed by current evidence, and benefits may extend to
those with more severe COPD.
Smoking cessation counselling plus either nicotine
replacement therapy or an antidepressant are effective ways
to help patients to stop smoking.
Inhaled therapy
Current evidence suggests that long-acting beta-agonists plus
inhaled corticosteroids (ICS) reduce moderate exacerbations,
and confirms that ICS may be associated with a risk of
pneumonia. Whether mortality is reduced remains unclear.
A combined regimen of tiotropium plus formoterol may be of
greater benefit to lung function and symptoms versus
tiotropium alone, but evidence to suggest a reduction in
mortality or exacerbations appears to be inconclusive.
Tiotropium may be more effective than salmeterol in terms of
exacerbations but the evidence is currently unclear.
Dry-powder delivery of tiotropium appears to be safe but there
may be safety concerns with delivery via mist inhaler.
Indacaterol is more effective than placebo and has shown non-
inferiority to tiotropium. Evidence suggests it is superior to
salmeterol and to formoterol, although mean differences did
not meet the clinical significance criteria stated in the full
version of NICE clinical guideline 101. Indacaterol is a
potential consideration for future NICE guidance reviews.
A NICE technology appraisal has recently recommended
roflumilast only in the context of research as part of a clinical
trial for adults with severe COPD.
Pulmonary rehabilitation
The benefits of longer versus shorter pulmonary rehabilitation
programmes appear to be inconclusive. Current evidence
seems unable to define an optimal programme length.
Evidence Update 5 – Chronic obstructive pulmonary disease (February 2012) 5
6. Effect on guidance
Potential No
Key message
change change
Pulmonary rehabilitation (continued)
Evidence suggests that there appears to be no clinical or cost
benefit of community-based over hospital-based rehabilitation,
and that the venue may be best determined by local access
preferences and transport links.
Inspiratory muscle training (IMT) appears to show empirical
benefits when used as the sole physical training modality.
However more evidence is needed, particularly concerning the
most suitable subgroups of patients, and whether IMT adds
usefully to standard pulmonary rehabilitation programmes is
unclear.
Pulmonary rehabilitation offers potential benefits even in
patients with the most severe COPD.
Preliminary evidence suggests that Nordic walking may be a
useful addition to current pulmonary rehabilitation strategies
but larger, longer-term studies are needed.
Vaccination and anti-viral therapy
Recent evidence appears to suggest that pneumococcal
vaccination in patients with COPD may not reduce the risk of
pneumonia, exacerbations or mortality. Large, well-designed
trials of newer polyvalent vaccines are needed.
Multidisciplinary management
Current evidence of the efficacy of home care by outreach
nursing for COPD appears to be inconclusive. Large, well-
designed studies with clearly defined populations and
interventions are needed.
Complex patient education programmes may be more
effective than simpler interventions particularly in patients with
more severe COPD. Further investigation of long-term
outcomes in wider patient groups may be useful.
Management of exacerbations of COPD
Evidence suggests that for oxygen therapy during
exacerbations, titration to an appropriate target is associated
with better outcomes than administering high flow oxygen.
Current evidence indicates a potentially high risk of death
around the time of an acute exacerbation, and that the critical
period may extend beyond the period of hospitalisation.
Pulmonary rehabilitation in patients who have recently
experienced an exacerbation may reduce hospital admissions
and possibly mortality.
Areas not currently covered by NICE guidance
Risk factors
Evidence suggests that residential dampness and mould may
be associated with lung health problems but further research is
needed.
Evidence Update 5 – Chronic obstructive pulmonary disease (February 2012) 6
7. 1 Commentary on new evidence
These commentaries analyse the key references identified specifically for the Evidence
Update, which are identified in bold text. Supporting references are also provided.
Definitions of clinically important effects
Interpretation of the new evidence should take into account that the full version of NICE
clinical guideline (CG) 101 considered the following differences in outcomes to be the
minimum that is clinically important:
15% relative risk reduction (RRR) in mortality
20% RRR in exacerbations
20% RRR in hospitalisations
4 point improvement (indicated by a negative difference) in St. George’s Respiratory
Questionnaire (SGRQ)
1 unit improvement in transitional dyspnoea index (TDI)
100 ml difference in forced expiratory volume in 1 second (FEV 1 ).
1.1 Diagnosing COPD
No new key evidence was found for this section.
1.2 Managing stable COPD
Smoking cessation
In a meta-analysis of 47 studies, Lee and Fry (2010) examined decline in FEV 1 among never
smokers, continued smokers, ex-smokers and quitters (those who discontinued smoking
between recruitment and follow up).
Never smokers had a lower rate of FEV 1 decline than continued smokers (10.8 ml/year less;
95% confidence interval [CI] 8.9 to 12.8), and the rate of decline of FEV 1 of continued
smokers was significantly more than in the other three groups (p < 0.001). Among the three
non-smoking groups there was no statistically significant difference in FEV1 decline,
suggesting that disease progression in ex-smokers and quitters was more closely aligned with
non-smokers than smokers.
The limitations of the review were; only one database was searched, many of the included
studies were solely in men, and a third of the studies were from before 1970.
Although the review was unable to confirm the benefits (or otherwise) of smoking cessation at
different stages of COPD severity, a recent study by Vestbo et al. (2011) examined data in
2163 patients from a previously reported prospective observational study (the ECLIPSE trial).
This study found that patients continuing to smoke were at greater risk of marked disease
progression irrespective of the Global Initiative for Chronic Obstructive Lung Disease (GOLD)
stage.
Together, these two studies strengthen the strong messages on smoking cessation in NICE
CG101, and indicate that even in severe COPD, stopping smoking may be of benefit. The
established link between smoking and death from cardiovascular disease (Anthonisen et al.
2005) adds further weight to this argument.
Evidence Update 5 – Chronic obstructive pulmonary disease (February 2012) 7
8. Strassman et al. (2009) performed a network meta-analysis (involving comparison of
treatments that were not compared directly in a trial setting) of 7372 patients from six studies
of smoking cessation interventions in COPD. In an efficacy ranking system (versus no
intervention/usual care), smoking cessation counselling (SCC) plus nicotine replacement
therapy (NRT) was deemed most effective (odds ratio [OR] = 5.08; 95% CI 4.32 to 5.97;
p < 0.001), with SCC plus antidepressant in second place (OR = 3.32; 95% CI 1.53 to 7.21;
p = 0.002). However, a direct comparison of these two regimens found no significant
difference in efficacy (p = 0.28). High-intensity and low-intensity counselling had the same
effect when combined with antidepressant, but high-intensity counselling was more effective
in the presence of NRT (OR = 1.81; 95% CI 1.04 to 3.15; p = 0.04).
Although a large number of databases were searched, the network meta-analysis results
were not based on direct experimental comparison of interventions and only involved a small
number of studies. The evidence suggests that SCC plus either NRT or antidepressant both
are equally effective smoking cessation interventions to offer patients, and there is little
evidence for the superiority of high-intensity over low-intensity counselling. The
recommendations in NICE CG101 to offer pharmacological therapy with appropriate support
are unlikely to be affected by this evidence.
Notably, varenicline was not included in the interventions looked at by Strassman et al.
(2009). Varenicline is a further smoking cessation treatment option and should be used in
accordance with ‘Varenicline for smoking cessation’ (NICE technology appraisal guidance
123). The European Medicines Agency recently confirmed that the benefits of varenicline as a
smoking-cessation medicine outweigh a slight reported increase in cardiovascular events.
The evidence overall suggests that stopping smoking is of benefit, even in people with severe
COPD, and there are a number of ways patients may be helped to do so.
Key references
Lee PN, Fry JS (2010) Systematic review of the evidence relating FEV1 decline to giving up smoking.
BMC Medicine 8: 84
Full text: www.biomedcentral.com/content/pdf/1741-7015-8-84.pdf
Strassmann R, Bausch B, Spaar A et al. (2009) Smoking cessation interventions in COPD: a network
meta-analysis of randomised trials. European Respiratory Journal 34: 634–40
Full text: www.erj.ersjournals.com/content/34/3/634.full.pdf+html
Supporting references
Anthonisen NR, Skeans MA, Wise RA et al. (2005) The effects of a smoking cessation intervention on
14.5-year mortality: a randomized clinical trial. Annals of Internal Medicine 142: 233–9
Full text: www.annals.org/content/142/4/233.full
Vestbo J, Edwards LD, Scanlon PD et al. (2011) Changes in forced expiratory volume in 1 second over
time in COPD. New England Journal of Medicine 365: 1184–92
Full text: www.nejm.org/doi/full/10.1056/NEJMoa1105482
Inhaled therapy
Combination therapy
In a meta-analysis of 18 randomised controlled trials (RCT) of 12,446 patients, Rodrigo et al.
(2009) investigated the safety and efficacy of combined long-acting beta 2 -agonists (LABA)
plus inhaled corticosteroids (ICS) versus LABA monotherapy in stable COPD. Compared with
LABA monotherapy, LABA plus ICS did not significantly reduce severe exacerbations (that is,
those needing hospitalisation or withdrawal; RR = 0.91; 95% CI 0.82 to 1.01) or all-cause
mortality (RR = 0.90; 95% CI 0.76 to 1.06). Potential limitations to the review were; the
included studies were as short as 8 weeks, the mortality event rate in most studies was very
low, and many studies were not designed or powered to look at mortality.
Evidence Update 5 – Chronic obstructive pulmonary disease (February 2012) 8
9. The review also analysed less severe exacerbations and found that in this subgroup a LABA
plus ICS regimen was associated with a significantly lower risk of moderate exacerbations
(that is, needing systemic corticosteroids) compared with LABA monotherapy (RR = 0.84;
95% CI 0.74 to 0.96; p = 0.008 – although the reduction in RR was less than the minimum
clinically important difference [MCID] of 20% indicated by the full version of NICE CG101).
There was however some evidence of heterogeneity between trials for this outcome. The
safety analysis revealed an increased risk of pneumonia with LABA plus ICS (RR = 1.63;
95% CI 1.35 to 1.98).
These findings largely agree with the TORCH study of LABA plus ICS (Calverley et al. 2007),
which did not establish a clear link between the combination regimen and reduced mortality
versus LABA alone but did find that exacerbations were reduced.
Overall, the evidence suggests that LABA plus ICS reduce moderate exacerbations, in line
with the intent of this regimen in NICE CG101, and are associated with a known risk of
pneumonia as already stated in current guidance. However it remains unclear if mortality is
reduced. This evidence is unlikely to affect current guideline recommendations.
Wang et al. (2011) performed a meta-analysis of eight RCTs (1868 patients; trial duration
ranged from 2 weeks up to 24 weeks) comparing a combined regimen of the long-acting
muscarinic antagonist (LAMA) tiotropium plus a LABA (formoterol) with tiotropium alone in
stable COPD. Tiotropium plus formoterol significantly improved average FEV 1 (weighted
mean difference [WMD] = 105 ml; 95% CI 69 to 142 ml; p < 0.0001), average FVC (WMD
135 ml; 95% CI 96 to 174; p < 0.0001) and trough FEV 1 (WMD = 53 ml; 95% CI 30 to 76;
p < 0.0001 – although this improvement was less than the MCID of 100 ml indicated by the
full version of NICE CG101) compared with tiotropium alone. The mean change in TDI was
also greater with tiotropium plus formoterol compared with tiotropium alone (WMD = 1.50;
95% CI 1.01 to 1.99; p < 0.0001). There were insufficient data for SGRQ to perform a meta-
analysis. Adverse events and exacerbations tended to be fewer with the combined regimen,
but this was not statistically significant.
These results suggest that lung function and symptoms (based on data for TDI only) may be
improved with a combined regimen of tiotropium plus formoterol over tiotropium alone, but
there was not enough evidence to suggest a reduction in mortality or exacerbations.
Key references
Rodrigo GJ, Castro-Rodriguez JA, Plaza V (2009) Safety and efficacy of combined long-acting beta-
agonists and inhaled corticosteroids vs long-acting beta-agonists monotherapy for stable COPD: a
systematic review. CHEST 136: 1029–38
Full text: www.chestjournal.chestpubs.org/content/136/4/1029.full.pdf+html
Wang J, Jin D, Zuo P et al. (2011) Comparison of tiotropium plus formoterol to tiotropium alone in stable
chronic obstructive pulmonary disease: a meta-analysis. Respirology 16: 350–8
Abstract: www.onlinelibrary.wiley.com/doi/10.1111/j.1440-1843.2010.01912.x/abstract
Supporting references
Calverley PMA, Anderson JA, Celli B (2007) Salmeterol and fluticasone propionate and survival in
chronic obstructive pulmonary disease. New England Journal of Medicine 356: 775–89
Full text: www.nejm.org/doi/full/10.1056/NEJMoa063070
Tiotropium
In an RCT of 7376 patients, Vogelmeier et al. (2011) compared tiotropium (18 micrograms
once daily) with salmeterol (50 micrograms twice daily) and found that time to the first
exacerbation was greater with tiotropium (187 days) versus salmeterol (145 days),
corresponding to a 17% risk reduction (hazard ratio [HR] = 0.83; 95% CI 0.77 to 0.90;
p < 0.001).
Evidence Update 5 – Chronic obstructive pulmonary disease (February 2012) 9
10. Interpretation of this evidence in the context of NICE guidance is complicated by the fact that
patients were allowed to continue treatment with inhaled corticosteroids during the study;
tiotropium plus ICS is not a regimen recommended in NICE CG101 and therefore any
potential effect of this evidence on current recommendations may not be clear. Further
information on this evidence can be found in the National Prescribing Centre’s (NPC) MeRec
Rapid Review 3501.
Two recent meta-analyses have examined the safety of dry-powder inhalers and mist inhalers
for the delivery of tiotropium.
Dry-powder delivery of tiotropium was investigated in a meta-analysis of 19 RCTs
(18,111 patients; trial duration ranged from 6 weeks to 48 months) by Rodrigo et al. (2009),
who found no increased risk of a composite of major adverse cardiovascular events
compared with controls (RR=0.96; 95% CI 0.82 to 1.12). Of the individual components of the
composite, there was no increased risk of cardiovascular death and non-fatal stroke, however
the trials were not set up to study this in detail. There was also no significant increase in the
risk of all-cause mortality (RR = 0.97; 95% CI 0.86 to 1.09). A 4-year RCT of tiotropium in
COPD (the UPLIFT study; Tashkin et al. 2008) was included in the meta-analysis, which in
fact found that the risk of serious cardiac events may be lower with tiotropium than with
placebo. The new evidence suggests that tiotropium via dry-powder inhaler does not appear
to increase risk of cardiovascular events or mortality, and current recommendations in NICE
CG101 regarding its use are unlikely to be affected.
There may, however, be evidence to suggest safety issues with tiotropium when delivered via
mist inhaler (Spiriva Respimat). In a meta-analysis of five RCTs (6522 patients), Singh et al.
(2011) found that mist inhaler delivery of tiotropium was associated with a significantly greater
risk of mortality compared with placebo (RR = 1.52; 95% CI 1.06 to 2.16; p = 0.02). The risk
was greater with a 10 microgram dose (RR = 2.15; 95% CI 1.03 to 4.51; p = 0.04) but the
5 microgram dose was also associated with elevated risk (RR = 1.46; 95% CI 1.01 to 2.10;
p = 0.04). There also appeared to be an elevated risk of cardiovascular death (RR = 2.05;
95% CI 1.06 to 3.99; p = 0.03) but low event rates for this outcome prevent definitive
conclusions.
The potential safety issues with tiotropium via mist inhaler may be a consideration for future
reviews of NICE CG101, particularly for patients with cardiovascular disease. Further
information about the evidence for these potential concerns can be found in the NPC’s
MeReC Rapid Review 4012.
A safety trial by Boehringer Ingelheim Pharmaceuticals is currently underway to investigate
concerns with tiotropium delivery via mist inhaler.
Key references
Rodrigo GJ, Castro-Rodriguez JA, Nannini LJ et al. (2009) Tiotropium and risk for fatal and nonfatal
cardiovascular events in patients with chronic obstructive pulmonary disease: systematic review with
meta-analysis. Respiratory medicine 103: 1421–9
Abstract: www.resmedjournal.com/article/S0954-6111(09)00162-0/abstract
Singh S, Loke YK, Enright PL et al. (2011) Mortality associated with tiotropium mist inhaler in patients
with chronic obstructive pulmonary disease: Systematic review and meta-analysis of randomised
controlled trials. British Medical Journal 342: d3215
Full text: www.bmj.com/content/342/bmj.d3215.full.pdf
Vogelmeier C, Hederer B, Glaab T (2011) Tiotropium versus salmeterol for the prevention of
exacerbations of COPD. New England Journal of Medicine 364: 1093–103
Full text: www.nejm.org/doi/full/10.1056/NEJMoa1008378
Supporting references
Tashkin DP, Celli B, Senn S et al. (2008) A 4-year trial of tiotropium in chronic obstructive pulmonary
disease. New England Journal of Medicine 359: 1543–54
Full text: www.nejm.org/doi/full/10.1056/NEJMoa0805800
Evidence Update 5 – Chronic obstructive pulmonary disease (February 2012) 10
11. Boehringer Ingelheim Pharmaceuticals. Comparison of tiotropium in the HandhiHaler versus the
respimat in chronic obstructive pulmonary disease (NCT01126437).
Further details available from: www.clinicaltrials.gov/ct2/show/NCT01126437
Indacaterol
INVOLVE (Dahl et al. 2010) was a 1-year RCT of 1732 patients which compared indacaterol
300 and 600 micrograms once daily, formoterol 12 micrograms twice daily and placebo for
52-weeks. At 12 weeks, both indacaterol groups showed a mean increase in trough FEV 1 of
170 ml (95% CI 130 to 200 ml; p < 0.001) versus placebo (primary outcome), exceeding the
trial’s pre-defined clinically important difference of 120 ml (note that 600 micrograms daily is
double the maximum dose of indacaterol licensed in the UK). Both doses of indacaterol
produced increases in FEV 1 over placebo 100 ml greater than that produced by formoterol
(p < 0.001), but the clinical relevance of this difference was questioned by the European
Medicines Agency (see EMA Assessment Report). In addition this comparison was not a
predefined primary or secondary endpoint, but a predefined exploratory objective of the study.
A range of clinical outcomes were reported as secondary endpoints (all versus placebo).
These are discussed further in the NPC’s On The Horizon Rapid Review 1828. All active
treatments were statistically significantly superior to placebo.
INHANCE (Donohue et al. 2010) was a 26-week RCT including 1683 patients who received
indacaterol 150 or 300 micrograms or placebo daily (double blind), or open-label tiotropium
18 micrograms once daily. At week 12, both doses of indacaterol improved trough FEV 1
compared to placebo (primary outcome) by 180 ml (98.75% CI 140 to 220 ml; p < 0.001).
Tiotropium improved trough FEV 1 compared with placebo by 140 ml (98.75% CI 100 to
180 ml). Both indacaterol doses were stated to be statistically significant for non-inferiority to
tiotropium for trough FEV 1 at 12 weeks (p < 0.001) and for superiority (p 0.01). However,
insufficient data are provided in the published report to evaluate this fully. The 40 ml
difference in improvement in mean trough FEV 1 over placebo between tiotropium and
indacaterol is substantially less than than MCID of 100 ml indicated by the full version of NICE
CG101. INHANCE is discussed further in the NPC’s On The Horizon Rapid Review 1828.
INTENSITY, a 3-month non-inferiority RCT of 1598 patients by Buhl et al. (2011) compared
indacaterol 150 micrograms and tiotropium 18 micrograms, both once daily. The rounded
treatment difference for trough FEV 1 (0 ml; 95% CI ml to 20 ml) met the predefined non-
inferiority margin of 55 ml (p < 0.001 for non-inferiority) but superiority was not demonstrated
(coprimary outcomes). Secondary outcomes included TDI and SGRQ. The mean difference in
TDI score between the two treatments was 0.58 (p < 0.001; 95% CI not stated). This is less
than the MCID of 1 point indicated by the full version of NICE CG101, but more patients
assigned to indacaterol showed 1 point or greater improvement from baseline (57.9% vs
50.1%; OR = 1.49; 95% CI 1.19 to 1.85; p < 0.001). The mean difference between the two
treatments in improvement in SGRQ from baseline was 2.1 (p < 0.001; 95% CI not stated).
This is also less than the MCID of 4 points indicated by the full version of NICE CG101, but
more patients assigned to indacaterol showed 4 points or more of improvement (50.5% vs
42.5%; OR = 1.43; 95% CI 1.15 to 1.78).
Indacaterol 150 micrograms daily was compared with salmeterol 50 micrograms twice daily in
INSIST, a 12-week RCT of 1123 patients by Korn et al. (2011). The primary efficacy outcome
was time-standardised area under the curve of FEV 1 values between 5 minutes and 11 hours
45 minutes after the morning dose at week 12. Indacaterol was statistically superior to
salmeterol in this outcome (adjusted mean difference 57 ml; 95% CI 35 to 79 ml; p < 0.001).
The key secondary efficacy variable was trough FEV 1 at 12 weeks. Indacaterol was
statistically superior to salmeterol (adjusted mean difference 60 ml; 95% CI 37 to 83 ml;
p < 0.001). This is less than the MCID of 100 ml indicated by the full version of NICE CG101.
Indacaterol produced a statistically superior improvement in TDI (adjusted mean difference
Evidence Update 5 – Chronic obstructive pulmonary disease (February 2012) 11
12. 0.63; 95% CI 0.30 to 0.97; p < 0.01) This is also less than the MCID of 1 point indicated by
the full version of NICE CG101, but more patients assigned to indacaterol showed 1 point or
more improvement from baseline (69.4% vs 62.7%; OR = 1.41; 95% CI 1.07 to 1.85;
p < 0.05).
Indacaterol 150 micrograms daily was compared with salmeterol 50 micrograms twice daily
and placebo in INLIGHT-2, a 6-month RCT of 1002 patients by Kornmann et al. (2011).
Indacaterol improved trough FEV 1 compared with placebo at 12 weeks (p < 0.001; primary
outcome, value not stated). The difference versus placebo in trough FEV 1 in the indacaterol
group was 60 ml greater than that in the salmeterol group at 12 weeks and 70 ml greater at
26 weeks (secondary outcomes, both p < 0.001; 95% CI not stated). These results are less
than the MCID of 100 ml indicated in the full version of NICE CG101. The between-group
difference in SGRQ score at 12 weeks was significantly different in favour of indacaterol
(p < 0.05). The absolute difference was not stated, but appears from a figure to be less than
the MCID of 4 points indicated by the full version of NICE CG101. More patients assigned to
indacaterol showed 4 points or more improvement from baseline (57.9% vs 46.8%;
OR = 1.59; 95% CI 1.12 to 2.25; p < 0.01). Indacaterol produced a statistically superior
improvement in TDI at 4 weeks and 12 weeks, but not at 26 weeks. The adjusted mean
difference at 12 weeks was 0.55 (p < 0.05; 95% CI not stated). This is also less than the
MCID of 1 point indicated in the full version of NICE CG101. Statistical analysis of differences
between active groups in the proportion of patients who showed 1 point or more improvement
from baseline was not presented.
Chapman et al. (2011) conducted INDORSE, a 26-week extension to INHANCE, among
415 of the patients randomised to either dose of indacaterol or to placebo in that trial. The
primary objective was to evaluate the 52-week safety of indacaterol (that is, over the
combined period of INDORSE and INHANCE). Among the secondary evaluations the two key
efficacy endpoints were trough FEV 1 at 52 weeks and time to first moderate or severe
exacerbation. The incidence and type of adverse events were stated to be generally
comparable across study groups, but no statistical analysis was presented. Distinct from
cough as an adverse event, cough that occurred within 5 minutes of participants inhaling the
study drug at clinic visits was recorded. This was observed in an average of 18.3% of patients
receiving indacaterol 150 micrograms, 23.6% of those receiving indacaterol 300 micrograms
and 1.9% of those receiving placebo (no statistical analysis presented). Difference in trough
FEV 1 from placebo at 52 weeks was 170 ml (95% CI 110 to 230 ml) for patients receiving
indacaterol 150 micrograms and 180 ml (95% CI 120 to 240 ml) for patients receiving
indacaterol 300 micrograms (p < 0.001 for both). Hazard ratios for time to first exacerbation
were not statistically significantly different from placebo, although exacerbation rates were
lower in the indacaterol 150 micrograms and 300 micrograms groups (0.39 and 0.38
exacerbations per year respectively) than in the placebo group (0.54 exacerbations per year;
p < 0.05). Improvements in total SGRQ scores were greater than 4 points in all three arms at
all time-points after 8 weeks (except for placebo at week 44). Mean scores with both
indacaterol doses were statistically significantly better than placebo at week 26 and week 44
but not at other time points (absolute differences not stated).
A safety meta-analysis by Donohue et al. (2011) pooled data from all published and
unpublished studies of indacaterol in COPD of at least 12 weeks duration completed at the
time of this analysis (some lasted up to 12 months), but did not employ a systematic review
methodology. Indacaterol doses studied were 75, 150, 300 and 600 micrograms daily (total
number of patients exposed to indacaterol = 4764). Other active treatments included in the
review were salmeterol 50 micrograms and formoterol 12 micrograms (both twice daily) and
tiotropium 18 micrograms once daily. The most common adverse events with indacaterol
were COPD worsening, nasopharyngitis, and headache; most cases were mild or moderate
and incidence was generally similar to placebo and other active treatments. The risks of acute
Evidence Update 5 – Chronic obstructive pulmonary disease (February 2012) 12
13. respiratory serious adverse events (leading to hospitalisation, intubation, or death), and major
adverse cardiovascular events were not significantly different from placebo with any of the
active treatments. The mean percentage of attended visits at which patients experienced
cough after inhalation of indacaterol ranged from 14.1% to 18.4% across the indacaterol dose
groups (specific data not presented), compared with 2% in the placebo group (no statistical
analysis presented). This suggests a number needed to harm of six to eight versus placebo.
Although broadly reassuring regarding safety (but note the incidence of cough after
inhalation), the limitations of this study should be noted; it was based on a relatively small
patient population taken from controlled trials, in which safety was not the primary endpoint.
Indacaterol therapy is a potential consideration for future reviews of NICE CG101.
Key references
Buhl R, Dunn LJ, Disdier C et al. (2011) Blinded 12-week comparison of once-daily indacaterol and
tiotropium in COPD. European Respiratory Journal 38: 797–803
Abstract: www.erj.ersjournals.com/content/early/2011/05/26/09031936.00191810.abstract
Chapman KR, Rennard SI, Dogra A et al. (2011) Long-term safety and efficacy of indacaterol, a long-
acting beta2-agonist, in subjects with COPD: a randomized, placebo-controlled study. Chest 140: 68–75
Abstract: www.chestjournal.chestpubs.org/content/140/1/68.abstract
Dahl R, Chung KF, Buhl R et al. (2010) Efficacy of a new once-daily long-acting inhaled beta2-agonist
indacaterol versus twice-daily formoterol in COPD. Thorax 65: 473–9
Full text: www.thorax.bmj.com/content/65/6/473.abstract
Donohue JF, Fogarty C, Lotvall J et al. (2010) Once-daily bronchodilators for chronic obstructive
pulmonary disease: indacaterol versus tiotropium. American Journal of Respiratory & Critical Care
Medicine 182: 155–62
Full text: www.ajrccm.atsjournals.org/content/182/2/155.full.pdf+html
Korn S, Kerwin E, Atis S et al. (2011) Indacaterol once-daily provides superior efficacy to salmeterol
twice-daily in COPD: a 12-week study. Respiratory Medicine 105: 719–26
Abstract: www.resmedjournal.com/article/S0954-6111(11)00057-6/abstract
Kornmann O, Dahl R, Centanni S et al. (2011) Once-daily indacaterol versus twice-daily salmeterol for
COPD: a placebo-controlled comparison. European Respiratory Journal 37: 273–9
Abstract: www.erj.ersjournals.com/content/early/2010/08/06/09031936.00045810.abstract
Supporting reference
Donohue JF, Singh D, Kornmann O et al. (2011) Safety of indacaterol in the treatment of patients with
COPD. International Journal of Chronic Obstructive Pulmonary Disease 6: 477–92
Full text: www.dovepress.com/safety-of-indacaterol-in-the-treatment-of-patients-with-copd-a8339
Roflumilast
NICE technology appraisal 244 has recently recommended roflumilast only in the context of
research as part of a clinical trial for adults with severe COPD (for the purposes of this
technology appraisal guidance defined as forced expiratory volume in 1 second [FEV 1 ] post-
bronchodilator less than 50% predicted) associated with chronic bronchitis with a history of
frequent exacerbations as an add-on to bronchodilator treatment. This should be referred to
as the latest guidance.
Pulmonary rehabilitation
Optimal duration
In a systematic review of five RCTs (451 patients) looking at optimal duration of pulmonary
rehabilitation in people with COPD, Beauchamp et al. (2011) found limited evidence to
suggest that longer duration rehabilitation programmes are of greater benefit than those of a
shorter length. The authors were unable to conduct a meta-analysis due to considerable
Evidence Update 5 – Chronic obstructive pulmonary disease (February 2012) 13
14. heterogeneity of outcomes and particularly the way programme length was defined across the
included studies (the definition of a ‘short’ programme ranged from 4 weeks to 3 months
duration, and the ‘long’ programmes ranged from 7 weeks to 18 months).
Of the four studies that considered health-related quality of life (HRQOL), three found
evidence that longer programmes were more beneficial. Two of these used the Chronic
Respiratory Questionnaire (CRQ), in which a difference of 0.5 was deemed clinically
significant by the authors. In one trial of 44 patients, the mean difference in total CRQ was
0.61 (95% CI 0.15 to 1.08); and in a second trial of 140 patients, significant improvement in
CRQ was noted for all domains but only dyspnoea showed clinical significance (a difference
of 0.53). The third trial (140 patients) noted a significant difference in disability of 12% with
longer versus shorter trials (1.53 vs1.71) using the Fitness Arthritis and Seniors Trial
functional importance inventory.
For exercise capacity, only two of four studies looking at this outcome found that patients
were more improved in longer programmes. One trial of 140 patients noted those in longer
programmes walked 30.5 m farther in a 6-minute walking distance (6MWD) than patients in
shorter programmes (although not achieving the 54 m stated by the authors to indicate clinical
significance). In a second trial of 27 patients, the longer programme led to a difference in
12-minute walking distance (12MWD) of 60 m at 26 weeks, and an increase of 92 m at
52 weeks (versus a decline of 47 m with the short programme). The authors were unable to
define an optimum programme length.
Although some of the evidence appears to suggest greater benefit of longer rehabilitation
programmes, limitations of the review including the absence of a meta-analysis, and lack of
clinical significance with some outcomes, mean that current recommendations in NICE
CG101 are unlikely to be affected. Detailed information on pulmonary rehabilitation can be
found in the British Thoracic Society’s pulmonary rehabilitation guideline (British Thoracic
Society Standards of Care Subcommittee on Pulmonary Rehabilitation 2001).
Key reference
Beauchamp MK, Janaudis-Ferreira T, Goldstein RS et al. (2011) Optimal duration of pulmonary
rehabilitation for individuals with chronic obstructive pulmonary disease - a systematic review. Chronic
respiratory disease 8: 129–40
Abstract: www.crd.sagepub.com/content/8/2/129.abstract
Hospital versus community
Waterhouse et al. (2010) conducted a powered, randomised 2 x 2 trial of 240 patients (mean
age ~69 years) comparing pulmonary rehabilitation in a hospital versus community setting,
followed by telephone or conventional follow-up. They found no significant difference in the
percentage change in the distance walked during an Endurance Shuttle Walk Test (designed
to walk people without encouragement at a predetermined speed to ensure they are at 85%
of their maximum oxygen capacity [VO 2 max]) relative to baseline between the hospital
(108.7%) and the community (90.95%) rehabilitation groups (mean difference 17.8%; 95% CI
24.3 to 59.9; p = 0.405). There was also no significant difference between the groups in
terms of the increase in the time that they were able to walk for post-rehabilitation. The
absence of any significant differences in these outcomes continued at 6-month 12-month and
18-month post-rehabilitation follow-ups, at which times there also appeared to be no
indication of an effect of telephone versus conventional follow-up. An economic analysis also
conducted by the authors indicated no cost advantage to either of the rehabilitation settings or
to telephone follow up. A post-hoc analysis found a strong trend (falling marginally short of
statistical significance) towards an effect on rehabilitation outcomes depending on the
rehabilitation team, which may warrant further investigation.
Evidence Update 5 – Chronic obstructive pulmonary disease (February 2012) 14
15. The evidence suggests that there seems to be no clinical or cost benefit of community-based
over hospital-based rehabilitation, and the venue may be best determined by local access
preferences and transport links. This evidence therefore reinforces current recommendations
in NICE CG101.
Key reference
Waterhouse JC, Walters SJ, Oluboyede Y et al. (2010) A randomised 2 x 2 trial of community versus
hospital pulmonary rehabilitation for chronic obstructive pulmonary disease followed by telephone or
conventional follow-up. Health Technology Assessment 14: 1–164
Full text: www.hta.ac.uk/project/1316.asp
Inspiratory muscle training
In a meta-analysis of 32 RCTs (830 patients), Gosselink et al. (2011) looked at the effect of
inspiratory muscle training (IMT) in patients with COPD. Significant improvements were found
in a number of outcomes including maximal inspiratory muscle strength (+13 cm H 2 O;
p < 0.001), respiratory muscle endurance time (+261 seconds; p < 0.001), 6MWD or 12MWD
(+32 m and +85 m respectively; p < 0.001), TDI (+2.8; p < 0.001) and quality of life measured
by CRQ (+3.8 units; p < 0.01). For inspiratory muscle strength and exercise capacity,
individuals with inspiratory muscle weakness (maximal inspiratory pressure < 60 cm H 2 O)
were more likely to improve.
This evidence suggests the potential of IMT in pulmonary rehabilitation, but may not yet
provide definitive answers as to whether IMT should be added to other forms of rehabilitation,
and especially as to whether there is a subgroup of patients with inspiratory muscle weakness
who may benefit. Further research is needed to evaluate IMT and whether those with muscle
weakness can feasibly be identified and treated effectively with this intervention.
Thomas et al. (2010) also investigated IMT as part of a systematic review of home-based
physiotherapy interventions. In a meta-analysis of the three RCTs (34 patients) included in
the review examining the use of IMT in the home setting, they found that IMT significantly
improved breathlessness score measured by TDI by 2.36 (95% CI 0.76 to 3.96) compared
with controls. Although this analysis suggests that home-based IMT may be effective,
because of potential limitations of the evidence (limited numbers of patients and treatment
heterogeneity between studies), more research is needed to determine whether IMT can be
added to or substituted for standard pulmonary rehabilitation techniques, before firm
recommendations can be made.
Overall, there may not yet be enough robust and conclusive evidence to consider including
IMT in future updates of NICE CG101.
Key references
Gosselink R, De Vos J, van den Heuvel SP et al. (2011) Impact of inspiratory muscle training in patients
with COPD: what is the evidence? European Respiratory Journal 37: 416–25
Abstract: www.erj.ersjournals.com/content/37/2/416.abstract
Thomas MJ, Simpson J, Riley R et al. (2010) The impact of home-based physiotherapy interventions on
breathlessness during activities of daily living in severe COPD: a systematic review. Physiotherapy 96:
108–19
Abstract: www.sciencedirect.com/science/article/pii/S0031940609001205
Severe COPD
Fernandez et al. (2009) conducted an RCT of 42 male patients (mean age 66 years in the
intervention group, 70 years in the control group) to examine the safety and efficacy of a
home-based pulmonary rehabilitation programme for patients with very severe COPD on
long-term oxygen therapy (LTOT). Although baseline characteristics were largely balanced
between the groups, some appeared to be outside of expected ranges for patients of this
Evidence Update 5 – Chronic obstructive pulmonary disease (February 2012) 15
16. disease severity (for example, medical research council dyspnoea scores of 2.6 in the
treatment arm and 2.3 in the control arm; body mass index [BMI] ~29; and 6MWD ~60% of
predicted), which potentially reduces the external validity of findings.
The rehabilitation programme included a simple set of home exercises and low-intensity
supervision comprising two hospital visits and four home visits over 2 months. Those
receiving rehabilitation showed a significant increase in 6MWD (313 ± 72 m vs
392 ± 82 m; p = 0.0001 [exceeding the 54 m difference stated by the authors to indicate
clinical significance]) and a significant improvement in HRQOL indicated by a reduction in the
SGRQ score (55.3 ± 15.0 vs 40.5 ± 13.8; p = 0.0001). No complications arose from
performing the exercises. This study appears to reinforce the recommendation in NICE
CG101 that pulmonary rehabilitation should be offered to all patients who consider
themselves functionally disabled by COPD, and serves as a reminder that this may extend to
those even with the most severe disease on LTOT.
Key reference
Fernandez AM, Pascual J, Ferrando C et al. (2009) Home-based pulmonary rehabilitation in very severe
COPD: Is it safe and useful? Journal of cardiopulmonary rehabilitation and prevention 29: 325–31
Abstract: www.journals.lww.com/jcrjournal/Abstract/2009/09000/Home_Based_Pulmonary_Rehabilitatio
n_in_Very_Severe.10.aspx
Nordic walking
Breyer et al (2009) performed an RCT of 60 patients (mean age ~60 years) with COPD
investigating the effect of Nordic walking (a walking technique involving specialised poles)
on daily physical activities (measured by a tri-axial accelerometer) and functional exercise
capacity (measured by 6MWD). After a 3-month training period, patients in the Nordic
walking group spent more time walking (14.9 ± 1.9 minutes/day) and standing (129 ±
2
26 minutes/day) and their intensity of walking also increased (0.40 ± 14 m/s ) compared
with baseline as well as with controls (all p < 0.01). 6MWD also increased (79 ± 28 m)
compared with baseline and controls (both p < 0.01). These improvements remained at
6-month and 9-month follow-up.
A number of issues may prevent definitive conclusions including the limited number of
patients and a lack of details about the intervention (whether Nordic walking continued during
follow up; what type of terrain was used; and the time of year). Data for pulmonary function,
BMI, HRQOL and GOLD status were not reported, and no long-term survival information was
given. A lack of previous studies of this intervention in COPD also meant that the trial could
not be powered appropriately.
This preliminary evidence suggests that Nordic walking may be a useful addition to current
pulmonary rehabilitation strategies and larger studies are now needed comparing the
intervention with other techniques, and looking at additional, longer term outcomes such as
survival, resource usage and patient satisfaction. There are no current implications for
NICE CG101.
Key reference
Breyer MK, Breyer-Kohansal R, Funk GC et al. (2010) Nordic Walking improves daily physical activities
in COPD: A randomised controlled trial. Respiratory research 11: 112
Full text: www.respiratory-research.com/content/pdf/1465-9921-11-112.pdf
Vaccination and anti-viral therapy
A Cochrane review of seven studies (1709 patients) by Walters et al (2010) examined the
use of injectable vaccines against pneumococcal infections in patients with COPD. From
an analysis of six studies (1372 patients) it was found that pneumococcal vaccination did
not significantly reduce the likelihood of developing pneumonia compared with controls
Evidence Update 5 – Chronic obstructive pulmonary disease (February 2012) 16
17. (OR = 0.72; 95% CI 0.51 to 1.01). A further analysis of two studies (216 patients) found
that reduction in likelihood of acute COPD exacerbations was also not significant
(OR = 0.58; 95% CI 0.30 to 1.13). For secondary outcomes, pooled results of three studies
(888 patients) did not show a significant reduction in all-cause mortality or death from cardio-
respiratory causes.
These conclusions appear to be counter to the recommendations in NICE CG101 that
pneumococcal vaccination should be offered to all patients with COPD. However any
potential impact on current guidance may be limited by the quality of the evidence; two
included studies were abstracts from which only the published abstract data were used, and
two studies were from the 1980s, when only 14-valent vaccines were used (modern vaccines
are 23-valent). Larger, well designed clinical trials are therefore needed of the newer
polyvalent vaccines in COPD (although this may be difficult in the UK where the 5-yearly
pneumococcal vaccine has become standard practice).
Key reference
Walters JAE, Smith S, Poole P et al. (2010) Injectable vaccines for preventing pneumococcal infection in
patients with chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews issue
11: CD001390
Full text: www.onlinelibrary.wiley.com/doi/10.1002/14651858.CD001390.pub3/pdf
Multidisciplinary management
Hospital at home
Wong et al. (2011) performed a Cochrane systematic review of nine RCTs (1498 patients)
investigating home care by outreach nursing for COPD. A pooled analysis of eight studies
found mortality was not significantly reduced at 12 months (OR = 0.72; 95% CI 0.45 to 1.15)
and from pooling five studies found no significant difference in hospitalisations (OR = 1.01;
95% CI 0.71 to 1.44). A further pooled analysis of four studies did however find a significant
improvement in HRQOL (mean difference [MD] = 2.61; 95% CI 4.82 to 0.40).
There was considerable heterogeneity between the included studies in terms of the inclusion
criteria (ranging from patients on LTOT with life expectancy < 2 years through to patients with
one respiratory symptom, an FEV 1 < 80% and FEV 1 /FVC < 70%) and the interventions
(ranging from two home visits by a respiratory nurse through to 1 hour/week home teaching
for 8 weeks followed by weekly phone calls for 8 weeks and monthly calls for the remainder of
the year). The heterogeneity between studies may limit any conclusions and there is unlikely
to be an impact on current recommendations in NICE CG101. To further investigate the
movement of long-term follow-up services into the community, longer and larger well-
designed studies are needed looking at clearly defined populations and intervention types.
Key reference
Wong CX, Carson KV, Smith BJ (2011) Home care by outreach nursing for chronic obstructive
pulmonary disease. Cochrane Database of Systematic Reviews issue 3: CD000994
Full text: www.onlinelibrary.wiley.com/doi/10.1002/14651858.CD000994.pub2/pdf
Education and self-management
In a Cochrane review of 5 studies (574 patients) Walters et al. (2010) investigated the effect
of action plans involving limited patient education only for exacerbations of COPD. The
intervention consisted of an educational session with the patient lasting up to 1 hour only, with
a resulting personal action plan. Participants receiving the intervention had greater use of
corticosteroids (mean difference [MD] 0.74; 95% CI 0.14 to 1.35) and antibiotics (OR 1.65;
95% CI 1.01 to 2.69) but this did not result in reduced hospital admissions (MD 0.23; 95% CI
–0.03 to 0.49). There was no mortality benefit, other benefits were minor and HRQOL was
Evidence Update 5 – Chronic obstructive pulmonary disease (February 2012) 17
18. largely unchanged. The evidence suggests that a single, short educational session is unlikely
to benefit health outcomes.
Rice et al. (2010) examined a more complex programme in a multicentre RCT of
743 patients (mean age ~70 years) with severe COPD. Although the authors refer to the
intervention as a ‘relatively simple disease management programme’ it was more intensive
than those looked at by Walters et al. (2010). Patients in the treatment arm received a single
1–1.5 hour education session, an action plan for self-treatment of exacerbations, and monthly
follow-up calls from a case manager.
After 1 year, among those receiving disease management the mean cumulative frequency of
hospitalisations and emergency department visits was 0.48 per patient compared with 0.82 in
usual care (difference 0.34; 95% CI 0.15 to 0.52; p < 0.001). The trial involved almost entirely
male and relatively high-risk patients, and was based in the USA. This evidence in terms of
the incorporation of case management and structured action plans, particularly for higher risk
patients, may be a consideration for future reviews of NICE CG101.
Further research may now be needed to investigate multidimensional and more intensive
educational programmes and action plans, looking at effects in wider patient groups on long-
term outcomes such as exacerbations and utilisation of healthcare resources.
Key references
Rice KL, Dewan N, Bloomfield HE et al. (2010) Disease management program for chronic obstructive
pulmonary disease: a randomized controlled trial. American journal of respiratory and critical care
medicine 182: 890–896
Full text: www.ajrccm.atsjournals.org/cgi/content/full/182/7/890
Walters JAE, Turnock AC, Walters EH et al. (2010) Action plans with limited patient education only for
exacerbations of chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews
issue 5: CD005074
Full text: www.onlinelibrary.wiley.com/doi/10.1002/14651858.CD005074.pub3/pdf
1.3 Management of exacerbations of COPD
Oxygen therapy during exacerbations
In an RCT of 405 patients (mean age 69 years) examining titrated versus high flow oxygen
treatment in the prehospital (ambulance/paramedic) setting, Austin et al. (2010) found that in
a sub-group analysis of patients with confirmed COPD (titrated, n = 97; high flow, n = 117),
mortality was reduced by 78% in patients receiving titrated oxygen treatment compared with
those who received high flow oxygen (relative risk = 0.22; 95% CI 0.05 to 0.91; p = 0.04).
Mortality in the confirmed COPD subgroup was 9% (11 deaths) in the high flow arm and 2%
(2 deaths) in the titrated oxygen arm (p = 0.04). Patients with COPD who received titrated
oxygen were also less likely to have respiratory acidosis (p = 0.01) and hypercapnia
(p = 0.02). There were some compliance issues in the study, particularly related to off-
protocol use of high flow oxygen at some point in the titration arm.
This evidence appears to support the assertion in the British Thoracic Society’s guideline for
emergency oxygen use in adult patients (O’Driscoll et al. 2008) that ‘oxygen is a treatment for
hypoxaemia, not breathlessness’ and ‘oxygen (should) be prescribed according to a target
saturation range’. The evidence also appears to agree with current recommendations in NICE
CG101 that oxygen should be given to keep the saturation level within the individualised
target range.
A recent comment piece by Beasley et al. (2011) summarising the latest evidence on high-
concentration oxygen therapy in COPD (including Austin et al. 2010) affirmed that the
preferred initial treatment in acute exacerbations of COPD is oxygen titration.
Evidence Update 5 – Chronic obstructive pulmonary disease (February 2012) 18
19. Key reference
Austin MA, Wills KE, Blizzard L et al. (2010) Effect of high flow oxygen on mortality in chronic
obstructive pulmonary disease patients in prehospital setting: randomised controlled trial. British Medical
Journal 341: c5462
Full text: www.bmj.com/content/341/bmj.c5462.full.pdf
Supporting reference
Beasley R, Patel M, Perrin K et al. (2011) High-concentration oxygen therapy in COPD. Lancet 10: 969–
70
Abstract: www.thelancet.com/journals/lancet/article/PIIS0140-6736(11)61431-1/fulltext
Prognosis following an exacerbation
Hoogendoorn et al. (2011) performed a meta-analysis of six cohort studies (57,144 patients)
and found that a severe exacerbation needing hospitalisation resulted in a weighted mean
case-fatality rate of 15.6% (95% CI 10.9 to 20.3%) with an average in-hospital mortality rate
of 6.7%. There were some potential methodological concerns with the review; no discussion
about which study types to include was apparent, no reports of quality assessment of the
studies were provided, and there was no mention of publication bias.
Within the possible limitations of the evidence, this study indicates the potentially high risk of
dying around the time of an acute exacerbation, and that the critical period appears to extend
beyond the duration of the hospitalisation. The evidence is unlikely to affect NICE CG101, but
emphasises the risks associated with severe exacerbations (in particular the continued
elevated risk after discharge), which should be managed according to current guidance.
An observational cohort study of 2138 patients by Hurst et al. (2010) provides further context,
noting that exacerbations increased with the severity of COPD. Frequent exacerbations were
observed in 22% of patients with GOLD stage 2 disease (exacerbation rate = 0.85 per person
during first year of follow-up), 33% with stage 3 (rate = 1.34), and 47% with stage 4
(rate = 2.00). It was also found that a history of exacerbations appeared to be the best
predictor of exacerbations at all stages of disease.
Taken together, the two studies show that those with a history of exacerbations and more
severe disease may potentially be more likely to experience exacerbations with increased
frequency, and that exacerbations may be associated with a high risk of death, even after
discharge.
Key reference
Hoogendoorn M, Hoogenveen RT, Rutten-van Molken MP et al. (2011) Case fatality of COPD
exacerbations: a meta-analysis and statistical modelling approach. European Respiratory Journal 37:
508–15
Abstract: www.erj.ersjournals.com/content/37/3/508.abstract
Supporting reference
Hurst JR, Vestbo J, Anzueto A et al. (2010) Susceptibility to exacerbation in chronic obstructive
pulmonary disease. New England Journal of Medicine 16: 1128–38
Full text: www.nejm.org/doi/pdf/10.1056/NEJMoa0909883
Pulmonary rehabilitation following an exacerbation
In a Cochrane review of nine trials (432 patients), Puhan et al. (2011) found that pulmonary
rehabilitation significantly reduced hospital admissions (OR = 0.22; 95% CI 0.08 to 0.58)
and mortality (OR = 0.28; 95% CI 0.10 to 0.84) in patients who had recently experienced
an exacerbation. This evidence reinforces the value of post-exacerbation rehabilitation and
may be a consideration in future reviews of NICE CG101, although the included trials were
small.
Evidence Update 5 – Chronic obstructive pulmonary disease (February 2012) 19
20. Key reference
Puhan MA, Gimeno-Santos E, Scharplatz M et al. (2011) Pulmonary rehabilitation following
exacerbations of chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews
issue 10: CD005305
Full text: www.onlinelibrary.wiley.com/doi/10.1002/14651858.CD005305.pub3/full
Areas not currently covered by NICE guidance
Risk factors
In a meta-analysis of 23 studies, Fisk et al. (2010) found that the presence of residential
dampness and mould may be linked with both bronchitis (summary estimate OR = 1.45; 95%
CI 1.34 to 1.56) and respiratory tract infections (summary estimate OR = 1.45; 95% CI 1.34 to
1.56). These values remained largely unchanged when the analyses were restricted to
studies controlling for major confounding variables (age, gender, smoking and socioeconomic
status). Some potential issues with the quality of the review should be considered when
interpreting the results (only one database was searched, the included studies were largely
cross-sectional along with some birth-cohort and case-control studies, and there was no
indication that studies were quality assessed). There was some evidence of publication bias
in the respiratory infection studies, however a further analysis to take this into account
indicated publication bias had little effect on the original summary estimates.
Bearing in mind the potential limitations of the study, this evidence suggests that dampness
and mould in the home may be associated with lung health problems, and these data may be
relevant to the aetiology of COPD, particularly in the context of the potential links between
COPD and poverty. Some patients with COPD may feel that their ill health is linked to
domestic mould or dampness, and in light of this evidence further research may be
warranted. This area is not currently addressed by NICE CG101.
Key reference
Fisk WJ, Eliseeva EA, Mendell MJ (2010) Association of residential dampness and mold with respiratory
tract infections and bronchitis: A meta-analysis. Environmental Health 9: 72
Full text: www.ehjournal.net/content/pdf/1476-069X-9-72.pdf
Evidence Update 5 – Chronic obstructive pulmonary disease (February 2012) 20
21. 2 New evidence uncertainties
During the development of the Evidence Update, the following evidence uncertainties were
identified that have not previously been listed on the NHS Evidence UK Database of
Uncertainties about the Effects of Treatments (DUETs).
Managing stable COPD
Smoking cessation
Smoking cessation and nicotine replacement therapy in COPD patients
www.library.nhs.uk/duets/ViewResource.aspx?resID=411746
Inhaled therapy
Tiotropium plus formoterol vs tiotropium alone in patients with stable COPD
www.library.nhs.uk/duets/ViewResource.aspx?resID=411748
Effects of long acting inhaled anticholinergics on cardiovascular events and mortality
among vulnerable subgroups at the highest risk of systemic anticholinergic effects
www.library.nhs.uk/duets/ViewResource.aspx?resID=411747
Pulmonary rehabilitation
Optimal duration of pulmonary rehabilitation in COPD patients for quality of life and
exercise capacity
www.library.nhs.uk/duets/ViewResource.aspx?resID=411749
Inspiratory muscle strength training vs endurance training in patients with COPD to
improve maximal inspiratory pressure and functional exercise capacity
www.library.nhs.uk/duets/ViewResource.aspx?resID=411750
Home-based physiotherapy interventions to reduce breathlessness during activities of
daily living in severe COPD
www.library.nhs.uk/duets/ViewResource.aspx?resID=411751
Vaccination and anti-viral therapy
Injectable vaccines for preventing pneumococcal infection in patients with chronic
obstructive pulmonary disease
www.library.nhs.uk/duets/ViewResource.aspx?resID=411737
Multidisciplinary management
Home care by outreach nursing for chronic obstructive pulmonary disease
www.library.nhs.uk/duets/ViewResource.aspx?resID=411071
Action plans with limited patient education only for exacerbations of chronic obstructive
pulmonary disease
www.library.nhs.uk/duets/ViewResource.aspx?resID=411739
Further evidence uncertainties for COPD can be found at www.library.nhs.uk/duets/ and in
the NICE research recommendations database at
www.nice.org.uk/research/index.jsp?action=rr.
DUETs has been established in the UK to publish uncertainties about the effects of treatment
which cannot currently be answered by referring to reliable up-to-date systematic reviews of
existing research evidence.
Evidence Update 5 – Chronic obstructive pulmonary disease (February 2012) 21
22. Appendix A: Methodology
Scope
The scope of this Evidence Update is taken from the scope of the reference guidance:
Chronic obstructive pulmonary disease. NICE clinical guideline 101 (2010). Available from
www.nice.org.uk/guidance/CG101
Searches
The literature was searched to identify studies and reviews relevant to the scope. Searches
were conducted of the following databases, covering the dates 20 August 2009 (the end of
the search period of the most recent annual Evidence Update) to 15 June 2011:
CINAHL
Cochrane Database of Systematic Reviews – Cochrane Library
Embase
MEDLINE
Table 1 provides details of the MEDLINE search strategy used, which was adapted to
search the other databases listed above. The search strategy was used in conjunction with
validated Scottish Intercollegiate Guidelines Network search filters for RCTs and systematic
reviews (www.sign.ac.uk/methodology/filters.html).
An additional 8 papers were also identified as key new evidence by the EUAG (Buhl 2011,
Chapman 2011, Dahl 2010, Donohue 2010, Korn 2011, Kornmann 2011, Puhan 2011,
Vogelmeier 2011). Commentaries on these papers are included in this Evidence Update.
Figure 1 provides details of the evidence selection process. The long list of evidence
excluded after review by the Update Adviser (the chair of the EUAG), and the full search
strategies, are available on request from contactus@evidence.nhs.uk.
Evidence Update 5 – Chronic obstructive pulmonary disease (February 2012) 22
23. Table 1 MEDLINE search strategy (adapted for individual databases)
1 exp Pulmonary Disease, Chronic Obstructive/
2 copd.ti,ab.
3 coad.ti,ab.
4 Bronchitis/
5 Chronic bronchitis/
6 (chronic adj5 (obstruct$ or limit#$)).ti.
(obstruct$ adj3 (airflow$ or airway$ or respirat$ or lung or pulmonary) adj2 (disease$ or
7 disorder$)).ti,ab.
8 Pulmonary emphysema/
9 emphysema.ti,ab.
10 "chronic bronchitis".ti,ab.
11 or/1-10
bronchial neoplasms/ or exp bronchiectasis/ or exp bronchiolitis/ or cystic fibrosis/ or lung diseases,
12 interstitial/ or lung neoplasms/
13 exp Sleep Apnea Syndromes/
14 Bronchopulmonary Dysplasia/
15 (cancer or neoplas$).ti.
16 "acute bronchitis".ti.
17 sleep apnea.ti.
18 (bronchiolitis or bronchiectasis).ti.
19 interstitial.ti.
20 (interstitial adj2 (lung or pulmonary or airway$ or airflow$)).ti.
21 exp Asthma/
22 asthma.ti.
23 or/12-22
24 11 not 23
25 letter/
26 editorial/
27 exp historical article/
28 Anecdotes as Topic/
29 comment/
30 case report/
31 animal/ not (animal/ and human/)
32 Animals, Laboratory/
33 exp animal experiment/
34 exp animal model/
35 exp Rodentia/
36 or/25-35
37 24 not 36
38 limit 37 to english language
39 (exp child/ or exp infant/) not exp adult/
40 38 not 39
Evidence Update 5 – Chronic obstructive pulmonary disease (February 2012) 23
24. Figure 1 Flow chart of the evidence selection process
EUAG – Evidence Update Advisory Group
Evidence Update 5 – Chronic obstructive pulmonary disease (February 2012) 24
25. Appendix B: The Evidence Update Advisory
Group and NHS Evidence project team
Evidence Update Advisory Group
The Evidence Update Advisory Group is a group of subject experts who review the prioritised
evidence obtained from the literature search and provide the commentary for the Evidence
Update.
Professor Sam H Ahmedzai – Chair
Professor of Palliative Medicine, Academic Unit of Supportive Care, School of Medicine, The
University of Sheffield
Professor Peter Barnes
Head of Respiratory Medicine, Imperial College London
Dr Kevin Gruffydd-Jones
GP Principal, Box Surgery, Box, Wiltshire
Dr Rod Lawson
Consultant in Respiratory and General Internal Medicine, Sheffield Teaching Hospital NHS
Foundation Trust
Professor Mike Morgan
Consultant Respiratory Physician, University Hospitals of Leicester NHS Trust, Glenfield
Hospital, Leicester
Professor Sally Singh
Head of Cardiac and Pulmonary Rehabilitation, University Hospitals of Leicester NHS Trust
Professor Jadwiga Wedzicha
Professor of Respiratory Medicine, University College London, Royal Free Campus
NHS Evidence project team
Marion Spring
Evidence Hub Manager
Russell Dube
Evidence Specialist
Fran Wilkie
Critical Appraiser
Patrick Langford
Editor
Andy Hutchinson and Katrina Simister
National Prescribing Centre (provided by NICE)
Evidence Update 5 – Chronic obstructive pulmonary disease (February 2012) 25